[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 341
1. del Rey J, Placer J, Vallmanya F, Pujol N, Prat E, Miró R, Gelabert A: Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial? BJU Int; 2010 Jul;106(1):49-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To estimate the relative risk of developing a second primary neoplasm, in particular lung cancer, after having non-muscle-invasive bladder cancer (NMIBC).
  • RESULTS: We found 231 patients with NMIBC, 39 of which had a second primary neoplasm: 10 lung cancer, one pancreas, one gastric, one pharynx, one liver, one parathyroid, one oesophageal, five basal cell carcinoma, three larynx, two colon, three rectal and 10 prostate.
  • In patients with lung cancer, NMIBC was the first primary tumour.
  • [MeSH-major] Carcinoma, Transitional Cell. Early Detection of Cancer. Lung Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Urinary Bladder Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Risk Factors


2. Ispas C, Yu J, Tarantino DR, Lara JF: Pathologic quiz case: a 44-year-old woman with a tubulovillous adenoma of the colon and liver and bone lesions. Small cell (neuroendocrine) carcinoma of the colon with metastasis and an associated, overlying villous adenoma. Arch Pathol Lab Med; 2005 Mar;129(3):412-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case: a 44-year-old woman with a tubulovillous adenoma of the colon and liver and bone lesions. Small cell (neuroendocrine) carcinoma of the colon with metastasis and an associated, overlying villous adenoma.
  • [MeSH-major] Adenoma, Villous / diagnosis. Bone Neoplasms / secondary. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / secondary. Colonic Neoplasms / diagnosis. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737043.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP: Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology; 2009 Mar;49(3):821-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.
  • Wnt/beta-catenin signaling plays an important role in liver development and regeneration.
  • Its aberrant activation, however, is observed in a subset of primary hepatocellular cancers (HCCs).

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):143-50 [18577996.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):703-10 [10487827.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):239-48 [15471898.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3619-31 [15782138.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1417-23 [15920538.001]
  • [Cites] Cell Tissue Res. 2006 Jan;323(1):71-9 [16160859.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):410-4 [16564914.001]
  • [Cites] Hepatology. 2006 Apr;43(4):817-25 [16557553.001]
  • [Cites] Hepatology. 2006 Mar;43(3):515-24 [16496320.001]
  • [Cites] Nat Med. 2006 Apr;12(4):410-6 [16532004.001]
  • [Cites] Dev Cell. 2006 Jun;10(6):759-70 [16740478.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):245-50 [10700176.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):357-61 [10888422.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1671-7 [11245482.001]
  • [Cites] Hepatology. 2001 May;33(5):1098-109 [11343237.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1763-73 [11375957.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1527-36 [11896101.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4863-71 [12101426.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5685-8 [12384525.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):44-50 [15305374.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] J Cell Biol. 1996 Mar;132(6):1133-49 [8601590.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3778-86 [16799619.001]
  • [Cites] Exp Cell Res. 2006 Nov 1;312(18):3620-30 [16952352.001]
  • [Cites] J Surg Res. 2006 Nov;136(1):125-35 [17023002.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1561-72 [17101329.001]
  • [Cites] Hepatology. 2007 Jan;45(1):42-52 [17187432.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):774-80 [16964294.001]
  • [Cites] Hepatology. 2007 Feb;45(2):361-8 [17256747.001]
  • [Cites] J Hepatol. 2007 May;46(5):849-57 [17275129.001]
  • [Cites] Hepatology. 2007 May;45(5):1298-305 [17464972.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8 [17481532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6 [17785413.001]
  • [Cites] Hepatology. 2007 Sep;46(3):740-8 [17663417.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1579-91 [17983805.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10831-9 [18006828.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):951-9 [18030363.001]
  • [Cites] Hepatology. 2008 Jan;47(1):288-95 [17929301.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jan;23(1):110-8 [18171349.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1451-61 [18316609.001]
  • [Cites] J Hepatol. 2008 May;48(5):780-91 [18313787.001]
  • [Cites] Mol Cancer. 2008;7:21 [18282277.001]
  • [Cites] Hepatology. 2008 May;47(5):1667-79 [18393386.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4287-95 [18519688.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jul;67(1):8-15 [18434184.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2800-5 [18539957.001]
  • [Cites] J Gastroenterol. 2008;43(5):378-89 [18592156.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • (PMID = 19101982.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA124414; United States / NCI NIH HHS / CA / R01 CA124414; United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NCI NIH HHS / CA / R01 CA124414-02; United States / NCI NIH HHS / CA / CA124414-02; United States / NIDDK NIH HHS / DK / 1R01DK62277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 6.3.1.2 / Glutamate-Ammonia Ligase
  • [Other-IDs] NLM/ NIHMS95668; NLM/ PMC2657345
  •  go-up   go-down


Advertisement
4. Brouwer J, Senft A, de Bree R, Comans EF, Golding RP, Castelijns JA, Hoekstra OS, Leemans CR: Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol; 2006 Mar;42(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The detection of distant metastases and second primary tumours at the time of initial evaluation changes the prognosis and influences the selection of treatment modality in patients with HNSCC.
  • In this observational cohort study we prospectively compared the yield of whole body (18)FDG-PET and chest CT to detect distant metastases and synchronous primary tumours.
  • Four patients were diagnosed with distant metastases or second primary tumours: CT as well as (18)FDG-PET identified one patient with lung metastases and another with primary lung cancer.
  • In addition, (18)FDG-PET detected second primary tumours in two patients (hepatocellular carcinoma and abdominal adenocarcinoma).
  • However increased uptake sites at (18)FDG-PET in lung, liver and pelvis in five patients were not confirmed by other imaging modalities.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Fluorodeoxyglucose F18. Head and Neck Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / radionuclide imaging. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266820.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Kidd M, Modlin IM, Mane SM, Camp RL, Eick G, Latich I: The role of genetic markers--NAP1L1, MAGE-D2, and MTA1--in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol; 2006 Feb;13(2):253-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Candidate marker gene expression (nucleosome assembly protein 1-like 1 [NAP1L1], melanoma antigen D2 [MAGE-D2], and metastasis-associated protein 1 [MTA1]) identified by Affymetrix transcriptional profiling was examined by QRT-PCR in SIC, liver, and lymph node (LN) metastases, colorectal carcinomas, and healthy tissues.
  • Immunohistochemical expression levels of MTA1 were analyzed quantitatively by a novel automated quantitative analysis in a tissue microarray of 102 gastrointestinal carcinoids and in a breast/prostate carcinoma array.
  • Increased levels (P < .05) were identified in both liver and LN metastases.
  • MAGE-D2 and MTA1 were increased (P < .05) in primary tumors and metastases and overexpressed in carcinomas.
  • Automated quantitative analysis demonstrated the highest levels of MTA1 immunostaining in malignant primary SICs and in metastases to the liver and LN.
  • These were significantly increased (P < .02) compared with nonmetastatic primary tumors.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoid Tumor / genetics. Cell Cycle Proteins / metabolism. Histone Deacetylases / metabolism. Intestinal Neoplasms / genetics. Intestine, Small. Nuclear Proteins / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Female. Genetic Markers. Humans. Male. Middle Aged. Nucleosome Assembly Protein 1. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424981.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-097050
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Genetic Markers; 0 / MAGED2 protein, human; 0 / NAP1L1 protein, human; 0 / Nuclear Proteins; 0 / Nucleosome Assembly Protein 1; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


6. Bondini S, Leoni S, Bolondi L: Squamous cell carcinoma of the liver: metastasis or primary neoplasm? J Clin Ultrasound; 2005 Dec;33(9):477-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the liver: metastasis or primary neoplasm?
  • [MeSH-major] Carcinoma, Squamous Cell / ultrasonography. Liver Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Liver / ultrasonography. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16281273.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


7. Fujii K, Kondo T, Yokoo H, Yamada T, Iwatsuki K, Hirohashi S: Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics; 2005 Apr;5(5):1411-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye.
  • To identify the proteomic alterations associated with carcinogenesis of hepatocellular carcinoma (HCC), we compared the protein expression profiles of nine HCC cell lines with those of primary cultured hepatocytes established from five individuals.
  • The proteins identified are involved in cell cycle regulation, binding to a tumor-suppressor gene product, fatty acid binding, and regulation of translation.
  • [MeSH-major] Carcinoma, Hepatocellular / chemistry. Cysteine / chemistry. Electrophoresis, Gel, Two-Dimensional / methods. Fluorescent Dyes / chemistry. Liver Neoplasms / chemistry. Proteome / analysis. Proteomics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Cells, Cultured. Female. Hepatocytes / cytology. Hepatocytes / physiology. Humans. Infant. Male. Mass Spectrometry. Middle Aged. Molecular Sequence Data


8. Lenartowicz M, Wieczerzak K, Krzeptowski W, Dobosz P, Grzmil P, Starzyński R, Lipiński P: Developmental changes in the expression of the Atp7a gene in the liver of mice during the postnatal period. J Exp Zool A Ecol Genet Physiol; 2010 Apr 1;313(4):209-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental changes in the expression of the Atp7a gene in the liver of mice during the postnatal period.
  • The main organ in mammals involved in copper metabolism is the liver.
  • It is known that copper metabolism in the liver is controlled by ATP7B, a P-type ATP-ase encoded by the Atp7b gene.
  • In this study we investigated the expression of the Atp7a gene in the liver during postnatal development in mice.
  • We analyzed expression of Atp7a gene in the livers from neonatal (P.05), young (P14) and adult (P240) mice using RT-PCR and real-time PCR method.
  • We found a transcript of the Atp7a gene in the liver of all investigated animals.
  • Moreover, we found that the expression of the Atp7a gene in the liver in mice is age-dependent and decreases during postnatal development.
  • Interestingly, the Atp7a expression in adult mice is very low in comparison with neonatal and young animals.
  • Western blot analysis revealed that Atp7a is expressed not only at mRNA level but also at the protein level in the liver of all investigated animals.
  • The expression of Atp7a gene and ATP7A protein was also confirmed in primary hepatocytes from adult mouse.
  • Demonstration of the hepatic Atp7a gene expression may shed light on new aspects of copper metabolism in the liver in mammals.
  • [MeSH-major] Adenosine Triphosphatases / metabolism. Aging / metabolism. Animals, Newborn / metabolism. Cation Transport Proteins / metabolism. Liver / metabolism
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cells, Cultured. Copper / metabolism. Hepatocytes / cytology. Hepatocytes / metabolism. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Male. Mice. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20084666.001).
  • [ISSN] 1932-5231
  • [Journal-full-title] Journal of experimental zoology. Part A, Ecological genetics and physiology
  • [ISO-abbreviation] J Exp Zool A Ecol Genet Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cation Transport Proteins; 0 / RNA, Messenger; 789U1901C5 / Copper; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.4 / Atp7a protein, mouse
  •  go-up   go-down


9. Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC: Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res; 2007 Sep 15;13(18 Pt 1):5368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma.
  • PURPOSE: KIAA0101 is a proliferating cell nuclear antigen-associated factor and involved in cell proliferation.
  • This study is to elucidate its role in the progression, early tumor recurrence (ETR), and prognosis of hepatocellular carcinoma (HCC).
  • EXPERIMENTAL DESIGN: KIAA0101 mRNA was measured by reverse transcription-PCR in 216 resected, unifocal, primary HCCs and its protein in 164 cases by immunohistochemistry.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carrier Proteins / metabolism. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875765.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / KIAA0101 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


10. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G: Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology; 2010 Apr;56(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.
  • AIMS: To study the relevance of periostin, known to be involved in epithelial-mesenchymal transition (EMT), in hepatocellular and bile duct cancer.
  • METHODS AND RESULTS: Immunohistochemical periostin expression was semiquantitatively analysed in normal liver tissue (n = 20), hepatocellular carcinoma (HCC; n = 91), liver-cell adenoma (n = 9), focal nodular hyperplasia (n = 13) and bile duct carcinomas (BDC; n = 116) using tissue microarrays.
  • Importantly, there was no strong periostin expression in benign liver tumours.
  • Strong stromal periostin expression was detected in 78/116 (67.2%) BDC and strong epithelial expression in 39/116 (33.6%) BDC. pT stage, differentiation grade and proliferation rate in primary BDC were independent of periostin expression.
  • [MeSH-major] Adenoma / metabolism. Bile Duct Neoplasms / metabolism. Carcinoma, Hepatocellular / metabolism. Cell Adhesion Molecules / metabolism. Focal Nodular Hyperplasia / metabolism. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Immunohistochemistry. Liver / metabolism. Liver / pathology. Male. Middle Aged. Prognosis. Survival Rate. Switzerland / epidemiology. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459570.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human
  •  go-up   go-down


11. Mangia A, Chiriatti A, Ranieri G, Abbate I, Coviello M, Simone G, Zito FA, Montemurro S, Rucci A, Di Leo A, Tommasi S, Berloco P, Xu JM, Paradiso A: H pylori status and angiogenesis factors in human gastric carcinoma. World J Gastroenterol; 2006 Sep 14;12(34):5465-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] H pylori status and angiogenesis factors in human gastric carcinoma.
  • AIM: To investigate H pylori expression in gastric cancer patients in relation to primary tumor angiogenic markers, such as microvessel density (MVD), thymidine phosphorylase (TP), vascular endothelial growth factor receptor-1 (VEGF-R1), p53 and circulating VEGF levels.
  • METHODS: Angiogenic markers were analyzed immunohistochemically in 56 primary gastric cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Bacterial / genetics. Antigens, Bacterial / metabolism. Bacterial Proteins / genetics. Bacterial Proteins / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Regulation, Bacterial. Gene Expression Regulation, Neoplastic. Humans. Immunoglobulin G / blood. Immunoglobulin G / genetics. Male. Microcirculation. Middle Aged. Receptors, Vascular Endothelial Growth Factor / genetics. Receptors, Vascular Endothelial Growth Factor / metabolism. Thymidine Phosphorylase / genetics. Thymidine Phosphorylase / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10566-73 [8144644.001]
  • [Cites] J Pathol. 2005 Nov;207(3):277-84 [16184519.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Scand J Gastroenterol Suppl. 1995;208:33-46 [7777803.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17771-7 [7629077.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] J Gastroenterol. 1996 Jun;31(3):329-32 [8726822.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Jun;12(6):425-8 [9195398.001]
  • [Cites] Dig Dis Sci. 1997 Aug;42(8):1652-9 [9286230.001]
  • [Cites] J Clin Invest. 1998 Apr 15;101(8):1604-13 [9541490.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):419-24 [11895856.001]
  • [Cites] Oncology. 2002;62(3):278-85 [12065876.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):499-505 [12209741.001]
  • [Cites] Dig Liver Dis. 2002 Jul;34(7):498-505 [12236483.001]
  • [Cites] Hepatogastroenterology. 2002 Sep-Oct;49(47):1453-6 [12239965.001]
  • [Cites] BMC Cancer. 2002 Apr 29;2:8 [11978184.001]
  • [Cites] Dig Liver Dis. 2002 Sep;34(9):621-5 [12405247.001]
  • [Cites] Int J Biol Markers. 2002 Jul-Sep;17(3):201-14 [12408472.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1317-23 [12429983.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):994-8 [12439912.001]
  • [Cites] Pol Merkur Lekarski. 2002 Sep;13(75):216-20 [12474574.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):145; author reply 147 [12538360.001]
  • [Cites] J Gastroenterol. 2003;38(1):28-36 [12560919.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2015-21 [12796363.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 28;311(4):809-14 [14623253.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):435-9 [14719080.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):1-10 [15015569.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Infect Immun. 1991 Sep;59(9):3343-5 [1879950.001]
  • [Cites] Cancer Res. 1991 Nov 1;51(21):5800-5 [1933850.001]
  • [Cites] J Clin Microbiol. 1992 Jan;30(1):192-200 [1734052.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10570-5 [1587837.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1992 Jul;11(7):583-8 [1396764.001]
  • [Cites] J Clin Microbiol. 1992 Dec;30(12):3230-3 [1452707.001]
  • [Cites] Cancer. 2000 May 15;88(10):2220-7 [10820342.001]
  • [Cites] Int J Cancer. 2000 Aug 1;87(3):322-7 [10897035.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):981-5 [11008919.001]
  • [Cites] Dig Liver Dis. 2000 Jun-Jul;32(5):378-83 [11030181.001]
  • [Cites] Oncol Res. 2000;12(1):33-41 [11061344.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):481-5 [11251969.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jun;2(6):457-66 [11389469.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):129-34 [11458276.001]
  • [Cites] Infect Immun. 1993 May;61(5):1799-809 [8478069.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5791-5 [8516329.001]
  • [Cites] Am J Gastroenterol. 1993 Nov;88(11):1916-9 [8237942.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):511-7 [8129036.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1997 Jun;29(3):214-9 [9646212.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):58-66 [9649459.001]
  • [Cites] J Clin Microbiol. 1998 Nov;36(11):3433-4 [9774616.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):28560-3 [9786845.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1998 Oct;30(5):484-9 [9836101.001]
  • [Cites] Am J Gastroenterol. 1994 Aug;89(8 Suppl):S116-28 [8048402.001]
  • (PMID = 17006982.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Biomarkers, Tumor; 0 / Immunoglobulin G; 0 / Tumor Suppressor Protein p53; 0 / VacA protein, Helicobacter pylori; 0 / Vascular Endothelial Growth Factor A; 0 / cagA protein, Helicobacter pylori; EC 2.4.2.4 / Thymidine Phosphorylase; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ PMC4088227
  •  go-up   go-down


12. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N: Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol; 2010 Apr;40(4):313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
  • OBJECTIVE: The combination chemotherapy consisting of cisplatin and etoposide, one of the standard regimens for small cell lung cancer, has been widely used to treat extrapulmonary poorly differentiated neuroendocrine carcinomas.
  • However, there were no prior reports limited to the hepatobiliary tract and pancreas as the primary sites.
  • METHODS: We reviewed the cases in our database from October 1995 to January 2009 and retrospectively examined the clinical data of patients, with unresectable or recurrent poorly differentiated neuroendocrine carcinoma arising from the hepatobiliary tract and pancreas, who received combination chemotherapy with cisplatin and etoposide as the first-line treatment.
  • The primary tumor site was the liver in 2 patients, gallbladder in 8 patients, pancreas in 10 patients and ampulla of Vater in 1 patient.
  • CONCLUSIONS: Cisplatin and etoposide combination as the first-line chemotherapy for hepatobiliary or pancreatic poorly differentiated neuroendocrine carcinoma had only marginal antitumor activity and relatively severe toxicity compared with previous studies on extrapulmonary poorly differentiated neuroendocrine carcinoma treated with the same regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047862.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC: Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology; 2009 Nov;50(5):1464-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma.
  • In this study we investigated the expression profiles of the EMT markers, the relationship between EMT markers and patient/tumor/viral factors, and the interplay between major EMT regulators in human hepatocellular carcinoma (HCC).
  • Reduced E-cadherin and nonmembranous beta-catenin expression, the hallmarks of EMT, were shown in 60.2% and 51.5% of primary HCC samples, respectively.
  • Overexpression of Snail, Twist, or Slug, the major regulators of EMT, was identified in 56.9%, 43.1%, and 51.4% of primary HCCs, respectively.
  • HCC cell lines with increased Snail and Twist expression (e.g., Mahlavu) exhibited a greater capacity for invasiveness/metastasis than cells with low endogenous Twist/Snail expression (e.g., Huh-7).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Metastasis / pathology. Nuclear Proteins / metabolism. Transcription Factors / metabolism. Twist Transcription Factor / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Cadherins / metabolism. Cell Differentiation / physiology. Cell Line, Tumor. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Male. Mesoderm / metabolism. Mesoderm / pathology. Mice. Mice, Nude. Middle Aged. Retrospective Studies. Transforming Growth Factor beta / metabolism. Transplantation, Heterologous. Vimentin / metabolism. beta Catenin / metabolism. gamma Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2009 Nov;50(5):1344-6 [19877297.001]
  • (PMID = 19821482.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Transforming Growth Factor beta; 0 / Twist Transcription Factor; 0 / Vimentin; 0 / beta Catenin; 0 / gamma Catenin; 0 / snail family transcription factors
  •  go-up   go-down


14. Hidaka H, Hotokezaka M, Nakashima S, Uchiyama S, Maehara N, Chijiiwa K: Sex difference in survival of patients treated by surgical resection for esophageal cancer. World J Surg; 2007 Oct;31(10):1982-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Squamous cell carcinoma accounts for most of the esophageal cancers in Japan and is often related to excessive smoking and drinking.
  • METHODS: There were 295 patients with a newly diagnosed primary malignant neoplasm of the esophagus treated at our University hospital between January 1978 and December 2005.
  • There were 185 patients (166 men, 19 women; age range 39-86 years) who underwent surgical resection for primary esophageal malignant neoplasms.
  • [MeSH-major] Esophageal Neoplasms / mortality. Neoplasms, Squamous Cell / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking. Esophagectomy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Postoperative Complications / epidemiology. Proportional Hazards Models. Risk Factors. Sex Factors. Smoking / epidemiology. Survival Analysis

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 2001 May;169(2):299-308 [11312147.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G471-9 [15064234.001]
  • [Cites] Annu Rev Immunol. 1998;16:395-419 [9597135.001]
  • [Cites] Arch Surg. 1999 Sep;134(9):935-8; discussion 938-40 [10487586.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1092-8 [11488795.001]
  • [Cites] Cancer Lett. 2006 Jan 18;231(2):158-68 [16399220.001]
  • [Cites] J Trauma. 2000 May;48(5):832-9; discussion 839-40 [10823526.001]
  • [Cites] Arch Surg. 1996 Nov;131(11):1186-91; discussion 1191-2 [8911259.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):387-92 [7920205.001]
  • [Cites] JAMA. 1992 Dec 23-30;268(24):3452-5 [1460735.001]
  • [Cites] Nat Med. 1996 Apr;2(4):457-60 [8597957.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):5923-9 [10454539.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):913-6 [11375898.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S212-9 [16127236.001]
  • [Cites] Carcinogenesis. 1998 Aug;19(8):1383-7 [9744533.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10057-62 [9294162.001]
  • [Cites] Crit Care Med. 1997 Jan;25(1):106-10 [8989185.001]
  • [Cites] Acta Anaesthesiol Scand. 1992 Apr;36(3):201-20 [1574967.001]
  • [Cites] J Trauma. 2000 May;48(5):932-7 [10823539.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3535-40 [11325813.001]
  • [Cites] Front Biosci. 2002 Jun 01;7:a117-25 [12045006.001]
  • [Cites] Arch Surg. 1998 Nov;133(11):1200-5 [9820351.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):526-30 [2736498.001]
  • [Cites] Mol Cell Endocrinol. 2002 Jul 31;193(1-2):129-35 [12161012.001]
  • [Cites] Shock. 2000 Aug;14(2):81-90 [10947147.001]
  • [Cites] Intensive Care Med. 2000 Feb;26(2):167-72 [10784304.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1986;39:13-32 [3465680.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Dec;27(12):1979-86 [14691386.001]
  • [Cites] J Surg Oncol. 1992 Jun;50(2):90-7 [1593891.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Int J Cancer. 1999 Aug 27;82(5):657-64 [10417762.001]
  • (PMID = 17676426.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, Uemoto S: Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol; 2010 Jul;37(1):89-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
  • Hepatocellular carcinoma (HCC) is known to be resistant to chemotherapy.
  • Survivin, a member of the inhibitor of apoptosis proteins, is overexpressed in most cancers but is absent in most normal adult tissue.
  • We confirmed induction of survivin expression in hepatoma in the N-diethylnitrosamine (DEN) induced rat and in the rat hepatoma cell line (K-251).
  • We examined cell proliferation after treatment with cisplatin (CDDP) in the presence and absence of siRNA or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 to suppress survivin or PI3K/Akt, respectively.
  • Expression of survivin was observed primary in the nuclei and in the cytoplasm with immunohistochemistry.
  • Expression of survivin was also observed primarily in the nuclei and in the cytoplasm of the K-251 rat hepatoma cell line.
  • Our results indicate that survivin expression via PI3K contributes to resistance to CDDP-induced apoptosis in a rat hepatoma cell line.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Hepatocellular / genetics. Cisplatin / pharmacology. Drug Resistance, Neoplasm / genetics. Liver Neoplasms, Experimental / genetics. Microtubule-Associated Proteins / genetics. Phosphatidylinositol 3-Kinases / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cells, Cultured. Diethylnitrosamine. Gene Expression Regulation, Neoplastic / drug effects. Male. RNA, Small Interfering / pharmacology. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514400.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Birc5 protein, rat; 0 / Microtubule-Associated Proteins; 0 / RNA, Small Interfering; 3IQ78TTX1A / Diethylnitrosamine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Otsuka H, Graham MM, Kogame M, Nishitani H: The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med; 2005 Dec;19(8):691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology consisted of 8 adenocarcinomas, 8 squamous cell carcinomas, 4 adenoid cystic carcinomas, 4 carcinoma ex pleomorphic adenomas, 2 mucoepidermoid carcinomas, 2 poorly differentiated carcinomas, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma and 1 melanoma.
  • RESULTS: In the initial staging group, all 12 primary lesions (100%) showed positive FDG uptake (5 squamous cell carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 carcinoma ex pleomorphic adenoma, 1 salivary duct carcinoma, 1 lymphoepithelial carcinoma).
  • Three patients (25%) had FDG positive distant disease (liver, bone, lymph nodes); surgery was canceled and therapy changed to chemoradiation.
  • A second primary lesion was detected in one patient (4%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444995.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Alexopoulou A, Koskinas J, Deutsch M, Delladetsima J, Kountouras D, Dourakis SP: Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature. Tumori; 2006 Jul-Aug;92(4):354-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature.
  • BACKGROUND: Acute liver failure is a rare complication of metastatic liver disease with a high mortality.
  • Recognition of malignant infiltration of the liver as the cause of acute liver failure could be a diagnostic challenge.
  • PATIENTS: The medical files of 5 patients with acute liver failure due to metastatic liver disease collected over a 4-year period (1997-2000) in our department were reviewed.
  • Liver imaging studies in 2 of the 5 patients were nondiagnostic and the malignant liver infiltration was confirmed postmortem.
  • Liver histology in all cases showed massive tumoral infiltration of the hepatic sinusoids with diffuse replacement of hepatocytes.
  • The primary tumors were colon, gastric, small cell lung, pancreas and cancer of unknown origin.
  • CONCLUSIONS: Malignant infiltration of the liver should be taken into account in the differential diagnosis of rapidly progressive liver failure.
  • Although effective chemotherapy has improved the survival of patients with metastatic liver disease, there has been no change in the course and outcome of acute liver failure due to malignant infiltration of the liver over the last 2 decades.
  • A proper diagnosis by liver biopsy is mandatory to prevent such patients from being considered for liver transplant.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Small Cell / secondary. Liver Failure, Acute / etiology. Liver Neoplasms / complications. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged, 80 and over. Biopsy. Female. Hepatic Encephalopathy / etiology. Humans. Jaundice / etiology. Liver Function Tests. Lung Neoplasms / pathology. Male. Medical Records. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036530.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


18. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
  • In our earlier work, we demonstrated that agrin, a multifunctional heparan sulfate proteoglycan, accumulates in hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC).
  • Here, we have examined the expression of agrin in metastatic liver carcinomas in comparison with primary liver tumors.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Agrin mRNA expression was measured in 11 HCC, 7 CCC, 11 CRCm, and 12 normal liver tissues.
  • As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules.
  • Thus, agrin immunohistochemistry may facilitate determination of primary versus metastatic origin in problematic liver cancer cases.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Agrin / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


19. Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert M, Mehta M, Eastern Cooperative Oncology Group: Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol; 2005 Dec 1;23(34):8870-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397).
  • PATIENTS AND METHODS: Patients with renal cell carcinoma, melanoma, or sarcoma; one to three brain metastases; and performance status of 0 to 2 were enrolled.
  • Exclusion criteria were leptomeningeal disease; metastases in medulla, pons, or midbrain; or liver metastases.
  • The primary end point was 3- and 6-month intracranial progression.
  • [MeSH-minor] Adult. Brain / pathology. Brain / physiopathology. Brain / surgery. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Cognition / physiology. Female. Follow-Up Studies. Humans. Kidney Neoplasms / pathology. Male. Melanoma / pathology. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Sarcoma / pathology. Survival Analysis. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314647.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V: Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol; 2010;5:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stool consistency and white and red blood cell count in stool were also assessed.
  • The primary endpoint was to reduce the incidence of diarrhea, defined by a CTC grade 2 or more, and the need for anti-diarrheal medication.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Double-Blind Method. Female. Humans. Incidence. Middle Aged. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Placebos. Probiotics / therapeutic use. Prospective Studies. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Treatment Outcome. Young Adult


22. Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M: Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer; 2009 Apr;64(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
  • OBJECTIVE: To evaluate the antitumor activity and safety profile of plitidepsin administered as a 1h weekly intravenous (i.v.) infusion of 3.2mg/m(2) to patients with small cell lung cancer (SCLC) who relapsed or progressed after one line of chemotherapy.
  • Objective response rate (primary efficacy endpoint) was evaluated according to response evaluation criteria in solid tumors (RECIST).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Depsipeptides / administration & dosage. Lung Neoplasms / drug therapy. Small Cell Lung Carcinoma / drug therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Salvage Therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692272.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; Y76ID234HW / aplidine
  •  go-up   go-down


23. Chan KY, Lai PB, Squire JA, Beheshti B, Wong NL, Sy SM, Wong N: Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol; 2006 Dec;19(12):1546-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.
  • Molecular characterizations of hepatocellular carcinoma have indicated frequent allelic losses on chromosomes 4q, 8p, 16q and 17p, where the minimal deleted regions have been further defined on 4q12-q23, 4q31-q35, 8p21-p22, 16q12.1-q23.1 and 17p13.
  • Despite these regions are now well-recognized in early liver carcinogenesis, few underlying candidate genes have been identified.
  • In an effort to define affected genes within common deleted loci of hepatocellular carcinoma, we conducted transcriptional mapping by high-resolution cDNA microarray analysis.
  • In 20 hepatocellular carcinoma cell lines and 20 primary tumors studied, consistent downregulations of novel transcripts were highlighted throughout the entire genome and within sites of frequent losses.
  • In primary hepatocellular carcinoma examined, a significant repression of MT1G by more than 100-fold was indicated in 63% of tumors compared to the adjacent nonmalignant liver (P = 0.0001).
  • In summary, transcriptional mapping by microarray indicated a number of previously undescribed downregulated genes in hepatocellular carcinoma, and highlighted potential candidates within common deleted regions.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Deletion. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Down-Regulation. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis


24. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol; 2008 Jan;19(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
  • BACKGROUND: This phase III study was designed to compare the combination paclitaxel (Taxol)-gemcitabine (PG) versus carboplatin-gemcitabine (CG) in patients with advanced inoperable non-small-cell lung cancer.
  • Primary end point was overall survival (OS).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. DIPHENHYDRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938425.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; 80061L1WGD / Cimetidine; 8GTS82S83M / Diphenhydramine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Gheorghe C, Stanescu C, Gheorghe L, Bancila I, Herlea V, Becheanu G, Voinea D, Iacob R, Lupescu I, Anghel R, Croitoru A, Popescu I: Preoperative noninvasive EUS evaluation in patients with esophageal cancer considered for esophagectomy. J Gastrointestin Liver Dis; 2006 Jun;15(2):137-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of the 220 patients, 41 patients, with no major comorbidities contraindicating esophagectomy already having been screened by abdominal and thoracic CT to disclose distant metastases, had EUS with the definite purpose of staging esophageal carcinoma and selecting adequate therapy.
  • Preoperative EUS staging changed the decision for surgery in 18 of 41 patients (44%) (p<0.0001) and allowed primary esophagectomy in only 6 patients (15%) (p<0.0001).
  • [MeSH-major] Adenocarcinoma / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Esophageal Neoplasms / ultrasonography. Esophagectomy. Patient Selection
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Preoperative Care. Prospective Studies

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16802008.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


26. Dokmak S, Cabral C, Couvelard A, Aussilhou B, Belghiti J, Sauvanet A: Pancreatic metastasis from nephroblastoma: an unusual entity. JOP; 2009;10(4):396-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Pancreatic metastasis from renal cell carcinoma is a well-known entity.
  • A metastatic nephroblastoma mainly affects the lung and the liver.
  • CASE REPORT: We report an extremely rare case of pancreatic metastases in a 20-year-old man who had a right nephroblastoma resected at 9 years of age and liver metastases treated by right hepatectomy at 18 years of age.
  • Imaging studies revealed no other localization except a 1.5 cm liver nodule.
  • The patient underwent pancreaticoduodenectomy and limited liver resection with an uneventful postoperative course.
  • Pathological examination confirmed pancreatic and liver metastases from a nephroblastoma composed of blastematous cells mixed with embryonic tubular structures without lymph node metastases.
  • After resection, the patient received adjuvant high dose chemotherapy with autologous hematopoietic stem-cell support.
  • After a 21-month follow-up, the patient was in good general condition but had liver recurrence without intra-pancreatic recurrence.
  • A nephroblastoma, like clear cell renal carcinoma, can be considered a possible etiology of pancreatic metastasis from a primary renal tumor.
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy / methods. Humans. Male. Pancreaticoduodenectomy / methods. Treatment Outcome. Young Adult


27. Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C: Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int; 2006 Nov;56(11):688-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the urinary bladder.
  • Primary large cell neuroendocrine carcinomas (LCNEC) of the urinary bladder are rare.
  • Reported herein is a case of a primary, pure LCNEC occurring in a man.
  • Two months after the primary transurethral resection, significant regrowth of the remnant mass was noted on CT, and the patient underwent a partial cystectomy.
  • In spite of three cycles of chemotherapy, the patient developed multiple metastases in the lung and liver 10 months postoperatively.
  • [MeSH-major] Carcinoma, Large Cell / secondary. Carcinoma, Neuroendocrine / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Hospice Care. Humans. Immunoenzyme Techniques. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040293.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Rizell M, Andersson M, Cahlin C, Hafström L, Olausson M, Lindnér P: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol; 2008 Feb;13(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
  • BACKGROUND: Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease.
  • METHODS: In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / drug therapy. Cholangiocarcinoma / drug therapy. Liver Neoplasms / drug therapy. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):649-53 [14991931.001]
  • [Cites] Liver Transpl. 2004 Oct;10(10):1301-11 [15376305.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1843-52 [16767220.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):986-91 [9744316.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1392-3 [12176410.001]
  • [Cites] Radiology. 2004 Jan;230(1):300-1; author reply 301-2 [14695404.001]
  • [Cites] World J Gastroenterol. 2005 Mar 14;11(10):1420-5 [15770715.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):226-30 [9705862.001]
  • [Cites] Transpl Int. 2005 Jan;18(1):89-94 [15612989.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Liver Transpl. 2001 Jun;7(6):473-84 [11443573.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4442-5 [15483011.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):789-93 [15868910.001]
  • [Cites] Acta Oncol. 2005;44(5):496 [16118084.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8421-5 [15623621.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3818-22 [16799623.001]
  • (PMID = 18307022.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


29. Liang YM, Li XH, Lü YL, Zhong M: [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. Zhonghua Yi Xue Za Zhi; 2005 Jan 12;85(2):96-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors].
  • OBJECTIVE: To investigate the morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors, and to conclude the diagnostic and differential diagnostic criteria for these morphologically similar tumors.
  • METHODS: Forty-six specimens of hepatic spindle cell tumors.
  • 20 primary tumors (43.4%), including 3 cases of sarcomatoid carcinoma (6.5%), 11 of angiosarcoma (23.9%), 2 of epithelioid hemangioendothelioma (5%), 1 of spindle cell carcinoid (2.2%), and 3 of undifferentiated sarcoma (6.5%).
  • and 26 metastatic malignant tumors (56.5%), including 20 cases of gastrointestinal stromal tumors (GIST, 43.4%), 3 of leiomyosarcoma (6.5%), 2 of malignant peripheral never sheath tumor (4.3%), and 1 of meningeal hemangiopericytoma (2.2%), resected during operation or collected during imaging-mediated liver puncture underwent hematoxylin-eosin staining, SP staining, and EnVision immunohistochemical staining.
  • RESULTS: Either primary or metastatic tumors showed extensive overlapping in histopathologic appearance, and hemangiopericytoma-like structure was the predominant pattern, which could be seen in nearly every kind of hepatic spindle cell tumors.
  • Most stromal tumor cases were CD117 positive, and existed the condition that the primary tumor was positive and the metastatic tumor was negative or vice versa or one part of specimen was positive but other part was negative.
  • Sarcomatoid carcinoma was positive for CK and vimentin.
  • Spindle cell carcinoid was positive for CK and neuroendocrine markers, such as synaptophysin and chromogranin A.
  • CONCLUSION: Primary angiosarcoma is the most common form of primary spindle cell tumor in liver, and metastatic GIST is predominant in hepatic metastatic spindle cell tumors.
  • [MeSH-major] Carcinoma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Biomarkers, Tumor. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774214.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


30. LI M, GUO K, KANG XN, SUN L, SHU H, LI RL, XU MH, LIU YK, QIN X, LI S: [Protein profiles of multinodular hepatocellular carcinoma with multicentric occurrence or with intrahepatic metastasis]. Zhonghua Gan Zang Bing Za Zhi; 2009 May;17(5):354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protein profiles of multinodular hepatocellular carcinoma with multicentric occurrence or with intrahepatic metastasis].
  • OBJECTIVE: To analyze the protein expression profiles of multinodular hepatocellular carcinoma (HCC) with multicentric occurrence (MO) or with intrahepatic metastasis (IM).
  • Gene ontology classification indicated that these proteins are associated to cell movement, signal transduction, oxidoreduction, lipid metabolism, and amino acid metabolism.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neoplasms, Multiple Primary / metabolism. Proteome / metabolism. Proteomics
  • [MeSH-minor] Adult. Blotting, Western. Electrophoresis, Gel, Two-Dimensional. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19497201.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


31. Sandhu SS, Symes A, A'Hern R, Sohaib SA, Eisen T, Gore M, Christmas TJ: Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int; 2005 Mar;95(4):522-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
  • OBJECTIVE: To present our results on managing loco-regional recurrence of renal cell carcinoma (RCC) with surgical excision, as local recurrence at the site of a previous nephrectomy is resistant to both systemic therapy and radiotherapy.
  • The median (mean, range) age at the time of local recurrence was 57.9 (57.4, 28.9-71.7) years, and the median interval from primary surgery 2.22 (3.88, 0.27-14.46) years.
  • RESULTS: Two patients were deemed inoperable because of direct invasion of the great vessels and the liver by tumour.
  • The remaining 14 patients had recurrence in residual adrenal tissue (two), para-aortic nodes (three), para-caval nodes (two), retrocaval nodes (one), renal bed (six), liver, spleen and stomach (one each), and diaphragm (two).
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Nephrectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15705072.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis


33. Petru E, Pasterk C, Reich O, Obermair A, Winter R, Breitenecker G: Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Arch Gynecol Obstet; 2005 Apr;271(4):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell carcinoma of the uterus and the vagina: experience with ten patients.
  • BACKGROUND: Small cell carcinomas (small-CCs) of the uterine cervix are rare and highly malignant neoplasms.
  • Two additional patients underwent primary radiotherapy.
  • Of the 7 patients who received chemotherapy, 5 developed progressive or recurrent disease in the paraaortic region (n=2), peritoneum (n=1), liver (n=1), or pelvis (n=1).
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


34. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs; 2007 Feb;25(1):77-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.
  • BACKGROUND: Arsenic trioxide induces growth inhibition and apoptosis in human hepatocellular carcinoma (HCC) cell lines.
  • METHODS: Inclusion criteria included advanced HCC patients to whom no standard palliative treatment can be offered, good organ function and liver function reserve.
  • Primary endpoint was the percentage of patients with 6-month disease stabilization.
  • [MeSH-major] Arsenicals / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Oxides / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Injections, Intravenous. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] Blood. 1999 Jan 1;93(1):268-77 [9864170.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6033-7 [10626785.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):1010-4 [14611680.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2001 Nov;23(6):487-9 [11859717.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8 [16234567.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):147-53 [12065089.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2396-410 [15800332.001]
  • [Cites] Hepatology. 1986 Jul-Aug;6(4):729-38 [2426173.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Mar;22(1):61-8 [12725324.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1687-92 [16130126.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]
  • [Cites] Liver. 1986 Jun;6(3):133-7 [2427909.001]
  • [Cites] Oncology. 2003;65(3):242-9 [14657598.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):421-7 [11905412.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4338-46 [15994145.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):327-30 [12201495.001]
  • [Cites] J Formos Med Assoc. 2004 Jul;103(7):483-95 [15318270.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1525-30 [10942401.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]
  • (PMID = 16937079.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


35. Knight B, Yeap BB, Yeoh GC, Olynyk JK: Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis; 2005 Oct;26(10):1782-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta.
  • Multifaceted evidence links the development of liver tumours to the activation and proliferation of adult liver progenitor (oval) cells during the early stages of chronic liver injury.
  • The aim of this study was to examine the role of the peroxisome proliferator activated receptors (PPARs): PPARalpha, delta and gamma, in mediating the behaviour of liver progenitor cells during pre-neoplastic disease and to investigate their potential as therapeutic targets for the treatment of chronic liver injury.
  • We observed increased liver expression of PPARalpha and gamma in concert with expanding oval cell numbers during the first 21 days following commencement of the choline deficient, ethionine supplemented (CDE) dietary model of carcinogenic liver injury in mice.
  • Both primary and immortalized liver progenitor cells were found to express PPARalpha, delta and gamma, but not gamma2, the alternate splice form of PPARgamma.
  • WY14643 (PPARalpha agonist), GW501516 (PPARdelta agonist) and ciglitazone (PPARgamma agonist) were tested for their ability to modulate the behaviour of p53-immortalized liver (PIL) progenitor cell lines in vitro.
  • In contrast, the PPARalpha agonist had no effect on PIL cell growth.
  • Administration of the PPARgamma agonist ciglitazone to mice fed with the CDE diet for 14 days resulted in a significantly diminished oval cell response and decreased fibrosis compared with those receiving placebo.
  • In contrast, GW501516 did not affect oval cell numbers or liver fibrosis, but inhibited CDE-induced hepatic steatosis.
  • In summary, PPARgamma agonists reduce oval cell proliferation and fibrosis during chronic liver injury and may be useful in the prevention of hepatocellular carcinoma.
  • [MeSH-major] Ethionine / toxicity. Liver / cytology. PPAR alpha / physiology. PPAR gamma / agonists. Receptors, Cytoplasmic and Nuclear / physiology. Stem Cells / cytology
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Line. Cell Survival / drug effects. Male. Mice. Mice, Inbred C57BL. Thiazoles / pharmacology. Thiazolidinediones / pharmacology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ETHIONINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15917308.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GW 501516; 0 / PPAR alpha; 0 / PPAR gamma; 0 / Ppard protein, mouse; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Thiazoles; 0 / Thiazolidinediones; 74772-77-3 / ciglitazone; WX1BN24WZT / Ethionine
  •  go-up   go-down


36. Lin A, Chen HX, Zhu CC, Zhang X, Xu HH, Zhang JG, Wang Q, Zhou WJ, Yan WH: Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med; 2010 Aug;14(8):2162-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is a major contributor to cancer incidence and mortality worldwide; however, potential roles of HLA-G in HCC remain unknown.
  • In the current study, HLA-G expression in 219 primary HCC lesions and their adjacent non-tumourous samples was analysed with immunohistochemistry.
  • Meanwhile, functional analysis of transfected cell surface HLA-G expression on NK cell cytolysis was performed in vitro.
  • HLA-G expression was observed in 50.2% (110/219) of primary HCC lesions, and undetectable in corresponding adjacent normal liver tissues.
  • Functional assay showed that HLA-G expression in transfected cells could dramatically decrease the NK cell cytolysis (P= 0.036), which could be markedly restored by the blockade of HLA-G (P= 0.004) and its receptor ILT2 (P= 0.019).
  • Its relevance to HCC progression might be result from the inhibition of NK cell cytolysis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Age Factors. Aged. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Blotting, Western. Cytotoxicity, Immunologic / drug effects. Enzyme-Linked Immunosorbent Assay. Female. HLA-G Antigens. Hep G2 Cells. Humans. Immunohistochemistry. K562 Cells. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Male. Middle Aged. Neoplasm Staging. Tissue Array Analysis. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
  • (PMID = 19799650.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC3823007
  •  go-up   go-down


37. Liu ZZ, Huang WY, Lin JS, Li XS, Lan X, Cai XK, Liang KH, Zhou HJ: Cell survival curve for primary hepatic carcinoma cells and relationship between SF(2) of hepatic carcinoma cells and radiosensitivity. World J Gastroenterol; 2005 Nov 28;11(44):7040-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell survival curve for primary hepatic carcinoma cells and relationship between SF(2) of hepatic carcinoma cells and radiosensitivity.
  • AIM: To establish the cell survival curve for primary hepatic carcinoma cells and to study the relationship between SF(2) of primary hepatic carcinoma cells and radiosensitivity.
  • METHODS: Hepatic carcinoma cells were cultured in vitro using 39 samples of hepatic carcinoma at stages II-IV.
  • After these cells were radiated with different dosages, the cell survival ratio and SF(2) were calculated by clonogenic assay and SF(2) model respectively.
  • After X-ray radiation of the fifth generation cells with 0, 2, 4, 6, 8 Gy, the cell survival rate was 41%, 36.5%, 31.0%, 26.8%, and 19%, respectively.
  • There was a negative correlation between cell survival and irradiation dosage (r = -0.973, P<0.05).
  • SF(2) ranged 0.28-0.78 and correlated with the clinical stage and pathological grade of hepatic carcinoma (P<0.05).
  • CONCLUSION: SF(2) correlates with the clinical stage and pathological grade of hepatic carcinoma and is a marker for predicting the radiosensitivity of hepatic carcinomas.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiotherapy. Cell Survival. Liver Neoplasms / pathology. Liver Neoplasms / radiotherapy. Radiation Tolerance
  • [MeSH-minor] Adult. Aged. Animals. Cell Culture Techniques. Dose-Response Relationship, Radiation. Humans. Middle Aged. Neoplasm Staging. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437614.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4717052
  •  go-up   go-down


38. Zhan XK, Sun YK, Zhang W, Wang JW: [Clinical analysis of 81 cases with primary small cell carcinoma of the esophagus]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):926-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 81 cases with primary small cell carcinoma of the esophagus].
  • OBJECTIVE: To evaluate the clinical characteristics, treatment and prognostic factors in patients with primary small cell carcinoma (SmCC) of the esophagus.
  • CONCLUSION: Esophageal small cell carcinoma is a rare but highly aggressive malignant tumor.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy. Esophagectomy. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173995.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JET protocol
  •  go-up   go-down


39. Goudard Y, Rouquie D, Bertocchi C, Daligand H, Baton O, Lahutte M, Terris B, Baranger B: [Malignant transformation of hepatocellular adenoma in men]. Gastroenterol Clin Biol; 2010 Mar;34(3):168-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant transformation of hepatocellular adenoma in men].
  • [MeSH-major] Adenoma, Liver Cell / pathology. Carcinoma, Hepatocellular / pathology. Cell Transformation, Neoplastic / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Cholecystectomy. Hepatectomy / methods. Humans. Male. Treatment Outcome. Weight Loss

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20189337.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


40. Morshed K, Szymański M, Siwiec H, Gołabek W: Laryngeal cancer in farmers from Lublin region of Poland. Ann Agric Environ Med; 2008;15(1):13-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The group included 148 patients with primary laryngeal squamous cell carcinoma (LSCC) diagnosed and treated in our institution in the years 1999-2002.
  • Nearly statistical significance was observed for the N stage (p=0.06) and for primary localisation of the tumour (p=0.05).
  • Distant metastases were observed in 7 (8.3%) of 84 farmers with LSCC, 6 to the lungs and one to the liver.
  • [MeSH-major] Agricultural Workers' Diseases / epidemiology. Agriculture. Carcinoma, Squamous Cell / epidemiology. Laryngeal Neoplasms / epidemiology. Occupational Diseases / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Poland / epidemiology. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581974.001).
  • [ISSN] 1232-1966
  • [Journal-full-title] Annals of agricultural and environmental medicine : AAEM
  • [ISO-abbreviation] Ann Agric Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


41. Boonsakan P, Thangnapakorn O, Tapaneeyakorn J, Kositchaiwat S, Bunyaratvej S: Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation. J Med Assoc Thai; 2007 Mar;90(3):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report combined hepatocellular and cholangiocarcinoma with sarcomatous transformation.
  • Combined hepatocellular and cholangiocarcinoma with sarcomatous transformation was first recognized in Ramathibodi Hospital in 2005.
  • This variant of carcinoma has been increasingly reported particularly from Asian countries.
  • The causative factors of hepatocarcinogenesis in Thailand include chronic viral hepatitis B or C, exposures to aflatoxin B1 and nitrosamine(s) and occasionally some certain nodular hepatocellular lesions due to arterial hyperperfusion.
  • It is suggested that the recent change of the Thai peoples' life style to an increased consumption of fast foods containing food preservatives especially nitrate or nitrite, the nitrosamine precursor may allow heavy exposure(s) to the chemical carcinogen(s) i.e. nitrosamine(s) leading to sarcomatous transformation of the carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Humans. Male. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427538.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


42. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, Zheng BJ, Lai PB, Lo CM, Chan KW, Guan XY: miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell; 2010 Dec 3;7(6):694-707
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
  • Here we describe the identification and characterization of such cells from hepatocellular carcinoma (HCC) using the marker CD133.
  • CD133 accounts for approximately 1.3%-13.6% of the cells in the bulk tumor of human primary HCC samples.
  • When compared with their CD133⁻ counterparts, CD133(+) cells not only possess the preferential ability to form undifferentiated tumor spheroids in vitro but also express an enhanced level of stem cell-associated genes, have a greater ability to form tumors when implanted orthotopically in immunodeficient mice, and can be serially passaged into secondary animal recipients.
  • Subsequent differential microRNA expression profiling of CD133(+) and CD133⁻ cells from human HCC clinical specimens and cell lines identified an overexpression of miR-130b in CD133(+) TICs.
  • Collectively, miR-130b regulates CD133(+) liver TICs, in part, via silencing TP53INP1.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma, Hepatocellular / metabolism. Carrier Proteins / metabolism. Glycoproteins / metabolism. Heat-Shock Proteins / metabolism. Liver Neoplasms / metabolism. MicroRNAs / metabolism. Neoplastic Stem Cells / metabolism. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Cell Line, Tumor. Cell Proliferation. Female. Humans. Liver / metabolism. Liver / pathology. Male. Mice. Mice, SCID. Middle Aged. Nuclear Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Cell Cycle. 2011 Feb 15;10(4):571-2 [21311235.001]
  • (PMID = 21112564.001).
  • [ISSN] 1875-9777
  • [Journal-full-title] Cell stem cell
  • [ISO-abbreviation] Cell Stem Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Heat-Shock Proteins; 0 / MIRN130 microRNA, human; 0 / MicroRNAs; 0 / Nuclear Proteins; 0 / Peptides; 0 / TP53INP1 protein, human; 0 / tumor protein 53-induced nuclear protein 1, mouse
  •  go-up   go-down


43. Dong-Dong L: Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro. Hepatogastroenterology; 2005 Jul-Aug;52(64):1186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro.
  • BACKGROUND/AIMS: We screened a novel gene MLC1 in human liver cancer tissue by differential display, and its cDNA full-length is 1600bp.
  • The purpose of this study is to find expression of MLC1 gene in human liver cancer tissue and the affect to SMMC7721 cell tumorigenesis in vivo and vitro.
  • METHODOLOGY: 250 cases of primary HCC tissue samples were studied for MLC1 mRNA and protein expression using RT-PCR, western blot, immunohistochemistry, MLC1 stable transfection into SMMC771, and SMMC7721 cells growth curve was analyzed by MTT method and SMMC7721 cells tumorigenesis in vivo.
  • CONCLUSIONS: MLC1 gene showed up-regulation expression at both the mRNA and protein levels in HCC tissues and that MLC1 plays an important role in the growth of hepatoma cell SMMC7721 in vitro and vivo.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / etiology. Liver Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. RNA, Messenger / metabolism. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001658.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MLC1 protein, human; 0 / Membrane Proteins; 0 / Mlc1 protein, mouse; 0 / RNA, Messenger
  •  go-up   go-down


44. Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, Hsu HC: RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology; 2008 Oct;48(4):1118-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.
  • To investigate the role of IMP3 in hepatocellular carcinoma (HCC), its protein expression in the surgically resected unifocal tumors of 377 HCC patients (296 men and 81 women) with ages ranging from 7 to 88 years (mean, 55.49 years) was analyzed by immunohistochemistry.
  • IMP3 was expressed in 255 (67.6%) of 377 resected unifocal primary HCCs.
  • Depletion of IMP3 with RNA interference in HCC cell line HA22T caused a decrease in cell motility, invasion, and transendothelial migration.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Child. Female. HMGA2 Protein / metabolism. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18802962.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


45. Xu L, Shi M, Zhang YQ, Li JQ: [Influence of surgical resection margin in hepatectomy on survival of patients with hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2006 Jan;28(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of surgical resection margin in hepatectomy on survival of patients with hepatocellular carcinoma].
  • OBJECTIVE: To compare the effect of different resection margin in hepatectomy on recurrence and survival of patients with hepatocellular carcinoma (HCC), and to determine an appropriate resection margin of hepatectomy for HCC patients.
  • Seventy-four patients in the wide-margin group had a distal resection margin of 2 cm and a proximal of 1 cm away from the edge of the primary tumor, while 78 patients in the narrow-margin group had a resection margin of < 1 cm away from the edge of the primary tumor provided that the margin was proven to be histologically free of cancer cells.
  • CONCLUSION: In hepatectomy for hepatocellular cell carcinoma patients, wide distal resection margin of 2 cm and a proximal of 1 cm away from the edge of the primary tumors according to direction of the portal vein flow may reasonably improve the overall and tumor-free survival.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737621.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  •  go-up   go-down


46. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM: Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology; 2009 Nov;50(5):1453-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.
  • Hepatocellular carcinoma (HCC) is a lethal malignancy for which there are no effective therapies.
  • Here, we show that cadherin-17 (CDH17) adhesion molecule is up-regulated in human liver cancers and can transform premalignant liver progenitor cells to produce liver carcinomas in mice.
  • RNA interference-mediated knockdown of CDH17 inhibited proliferation of both primary and highly metastatic HCC cell lines in vitro and in vivo.
  • The antitumor mechanisms underlying CDH17 inhibition involve inactivation of Wnt signaling, because growth inhibition and cell death were accompanied by relocalization of beta-catenin to the cytoplasm and a concomitant reduction in cyclin D1 and an increase in retinoblastoma.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Hepatocellular / pathology. Cell Proliferation. Liver Neoplasms / pathology. Signal Transduction / physiology. Wnt Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Cell Line, Tumor. Female. Gene Knockdown Techniques. Humans. Male. Mice. Mice, Nude. Middle Aged. Phenotype. Transplantation, Heterologous. beta Catenin / antagonists & inhibitors. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2006 Jul;11(7):1215-29 [16699959.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:251-61 [16869761.001]
  • [Cites] Cell Mol Life Sci. 2006 Jul;63(13):1564-73 [16791429.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5248-52 [16951245.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):94-9 [17063305.001]
  • [Cites] J Mol Biol. 2007 Jul 6;370(2):220-30 [17512947.001]
  • [Cites] Hepatology. 2007 Jul;46(1):200-8 [17596871.001]
  • [Cites] Bioinformatics. 2007 Jul 1;23(13):i450-8 [17646330.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1873-80 [17828401.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):90-6 [18043262.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):4-8 [18182973.001]
  • [Cites] J Mol Biol. 2008 Apr 18;378(1):44-54 [18342884.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 May;20(4):275-83 [18353622.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1752-63 [18471552.001]
  • [Cites] Proteomics. 2008 May;8(10):2136-49 [18425728.001]
  • [Cites] Mutat Res. 2008 May 31;653(1-2):6-13 [18467159.001]
  • [Cites] Cell. 2008 Nov 28;135(5):852-64 [19012953.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Cell. 2009 Mar 20;136(6):1136-47 [19303855.001]
  • [Cites] Hepatology. 2000 Jan;31(1):173-81 [10613743.001]
  • [Cites] Gut. 2001 Jul;49(1):73-81 [11413113.001]
  • [Cites] World J Gastroenterol. 2001 Oct;7(5):630-6 [11819844.001]
  • [Cites] Cancer Sci. 2003 May;94(5):425-30 [12824888.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):334-41 [12845670.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):618-24 [14623315.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 1;148(1):80-4 [14697646.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):562-8 [15178443.001]
  • [Cites] Cancer Lett. 2004 Aug 30;212(2):253-9 [15279905.001]
  • [Cites] J Clin Microbiol. 1987 Nov;25(11):2140-4 [2447120.001]
  • [Cites] Science. 1994 Apr 15;264(5157):430-3 [8153632.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1353-69 [8207063.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):483-9 [15701831.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):717-22 [16044349.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1582-95 [16710476.001]
  • [ErratumIn] Hepatology. 2010 Jan;51(1):358
  • (PMID = 19676131.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / P01 CA013106; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA13106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDH17 protein, human; 0 / Cadherins; 0 / Cdh17 protein, mouse; 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ HHMIMS353854; NLM/ PMC3328302
  •  go-up   go-down


47. Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD: Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer; 2008 Jun;60(3):374-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
  • OBJECTIVE: To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks), antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h continuous i.v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC).
  • PFR (primary efficacy endpoint) and objective response rate (secondary efficacy endpoint) were evaluated according to RECIST, while the toxic profile of plitidepsin was assessed using the NCI-CTC, version 2.0.
  • One patient was responder for the primary (PFR at 13+/-1 weeks) and secondary efficacy endpoint (stable disease according to RECIST).
  • Other two patients were non-responders for the primary efficacy endpoint, but had stable disease (not confirmed at weeks 13+/-1 due to previous withdrawal due to adverse events).
  • The most common side effects were anemia, and asymptomatic and non-cumulative increases of gamma-glutamyltransferase (GGT) and liver transaminase levels.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Depsipeptides / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Urochordata
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Animals. Disease Progression. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Transaminases / blood. gamma-Glutamyltransferase / blood


48. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol; 2007 Nov;8(11):975-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
  • We aimed to assess the activity and safety of axitinib in patients with metastatic renal-cell cancer who had failed on previous cytokine-based treatment.
  • The primary endpoint was objective response (ie, percentage of patients with confirmed complete response or partial response by use of Response Evaluation Criteria In Solid Tumors [RECIST] criteria.
  • INTERPRETATION: Axitinib shows clinical activity in patients with cytokine-refractory metastatic renal-cell cancer.
  • [MeSH-major] Bone Neoplasms / drug therapy. Carcinoma, Renal Cell / drug therapy. Imidazoles / therapeutic use. Indazoles / therapeutic use. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Enzyme Inhibitors / adverse effects. Enzyme Inhibitors / therapeutic use. Female. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Interleukin-2 / administration & dosage. Interleukin-2 / adverse effects. Lymphatic Metastasis. Male. Middle Aged. Treatment Outcome


49. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary angiosarcomas of the spleen are rare and almost always fatal.
  • The differential diagnosis includes a variety of benign and malignant vascular proliferations (littoral cell angioma and Kaposi's sarcoma) as well as metastatic tumors.
  • The liver is the most common site.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • However, histopathologic examination of the specimen showed the tumor to be of a primary angiosarcoma.
  • [MeSH-major] Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


50. Kunimura T, Yoshida T, Sugiyama T, Morohoshi T: The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma. J Gastrointest Cancer; 2009;40(3-4):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma.
  • MATERIALS AND METHODS: CD44s expression was measured on immunohistochemistry in tumors from 65 patients with primary colorectal carcinomas.
  • However, the CD44s expression showed significantly adverse relationship with lymph node metastasis (p < 0.05) and liver metastasis (p < 0.01), respectively.
  • CONCLUSION: The loss of CD44s expression in cancer cells in the deepest invaded area is a good marker for predicting potential metastasis to lymph nodes and liver in T3 CRC.
  • [MeSH-major] Antigens, CD44 / biosynthesis. Carcinoma / metabolism. Carcinoma / secondary. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 1998 Mar;33(3):301-9 [9548625.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1250-4; discussion 1254-5 [11005492.001]
  • [Cites] J Cell Biol. 1993 Jan;120(1):227-33 [8416989.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3922-8 [7518345.001]
  • [Cites] Pathol Int. 2009 Apr;59(4):241-6 [19351367.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] Cancer Invest. 2004;22(6):878-85 [15641486.001]
  • [Cites] Mol Pathol. 1998 Aug;51(4):191-200 [9893744.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):212-5 [10656728.001]
  • [Cites] Cell. 1989 Mar 24;56(6):1057-62 [2466575.001]
  • [Cites] Histopathology. 2005 Jan;46(1):24-30 [15656882.001]
  • [Cites] Oral Oncol. 2000 Nov;36(6):545-9 [11036249.001]
  • [Cites] J Craniofac Surg. 2002 Jan;13(1):85-9 [11887001.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1147-55 [8863664.001]
  • (PMID = 19937401.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor
  •  go-up   go-down


51. Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H: Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer; 2008 Nov 4;99(9):1462-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma.
  • In this study, we investigated HLA class I expression in oesophageal squamous cell carcinoma (ESCC) (n=70) and in their metastatic lesions (lymph nodes (n=40) and liver (n=3)), by immunohistochemistry with anti-HLA class I monoclonal antibody (EMR8-5).
  • As a result, the downregulation of HLA class I expression in primary lesions of ESCC was observed in 43%, and that in metastatic lymph nodes was noted in 90%.
  • Furthermore, patients with preserved HLA class I expression in primary tumours showed a better survival in comparison to those with downregulated HLA class I molecules (P<0.01).
  • Furthermore, multivariate analysis using Cox's proportional hazards model revealed that the downregulated expression of HLA class I in primary lesions was an independent, unfavourable prognostic factor (P<0.01).
  • In conclusion, the downregulation of HLA class I expression frequently occurred in primary tumour and, to a greater extent, in metastatic lesions of patients with ESCC and was associated with patient survival.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Esophageal Neoplasms / immunology. Histocompatibility Antigens Class I / analysis
  • [MeSH-minor] Adult. Aged. Down-Regulation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer Suppl. 1991;6:95-100 [2066187.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):729-36 [1985791.001]
  • [Cites] J Clin Pathol. 1995 Jun;48(6):539-44 [7665697.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):141-5 [8695222.001]
  • [Cites] Immunol Today. 1997 Feb;18(2):89-95 [9057360.001]
  • [Cites] Br J Cancer. 1997;76(7):836-44 [9328140.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):582-7 [9421352.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):745-54 [10079252.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):67-72 [15671529.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):498-504 [15701833.001]
  • [Cites] Cancer Immunol Immunother. 2006 Aug;55(8):891-9 [16187081.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9281-9 [16982773.001]
  • [Cites] J Gastrointest Surg. 1997 Jul-Aug;1(4):316-23 [9834364.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1374-80 [16995877.001]
  • [Cites] J Urol. 2007 Apr;177(4):1269-72; discussion 1272 [17382705.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:264-8 [17445216.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1424-30 [17645781.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4110-7 [17827461.001]
  • [Cites] Cancer Immunol Immunother. 2008 Feb;57(2):197-206 [17622526.001]
  • [Cites] Cancer Immunol Immunother. 2008 May;57(5):601-9 [17874100.001]
  • [Cites] J Surg Oncol. 2008 Apr 1;97(5):451-5 [18247377.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1448-54 [18452554.001]
  • [Cites] Cancer Immunol Immunother. 2008 Nov;57(11):1719-26 [18408926.001]
  • [Cites] Cancer Immunol Immunother. 2008 Dec;57(12):1903-10 [18317754.001]
  • [Cites] Adv Immunol. 2000;74:181-273 [10605607.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):833-46 [11560998.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1615-23 [11577000.001]
  • [Cites] Surgery. 2003 May;133(5):486-94 [12773976.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • (PMID = 18841157.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC2579690
  •  go-up   go-down


52. Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA: Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis; 2006;23(7-8):357-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status.
  • EphA2 is a transmembrane receptor tyrosine kinase that functions in the regulation of cell growth, survival, angiogenesis, and migration and EphA2 targeting has been proposed as a novel therapeutic strategy for neoplasms that overexpress this protein.
  • EphA2 overexpression has been correlated with increased invasive and metastatic ability in pancreatic cancer cell lines.
  • We collected clinicopathologic data and paraffin-embedded materials from 98 patients with primary and/or metastatic pancreatic cancer and performed immunohistochemical labeling for EphA2 protein.
  • When evaluated specifically for labeling intensity, primary and metastatic carcinomas were more strongly positive compared to benign ducts and PanIN lesions (P < 0.00001 and P < 0.01, respectively) and poorly differentiated carcinomas were more strongly positive for EphA2 than well and moderately differentiated tumors (P < 0.005).
  • When primary carcinomas without metastatic disease were specifically compared to carcinomas with associated metastatic disease, the advanced carcinomas showed relatively less strong positive labeling for EphA2 (P < 0.008).
  • Moreover, decreased EphA2 labeling was more commonly found in liver (P < 0.002), lung (P < 0.004) or peritoneal metastases (P < 0.01) as compared to distant lymph node metastases (P < 0.01).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):G824-32 [9357823.001]
  • [Cites] Cell Growth Differ. 1999 Sep;10(9):629-38 [10511313.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):757-66 [15359289.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):226-31 [15671550.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2684-94 [15829979.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2943-50 [16080548.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):548-54 [15846069.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):34008-18 [16051609.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):278-86 [16061279.001]
  • [Cites] Adv Surg. 2005;39:223-44 [16250554.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):541-51 [16254188.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1884-6 [16166198.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7859-68 [16103880.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42375-82 [16236711.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):353-60 [16428472.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):89-92 [11115575.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1833-8 [11280733.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):798-802 [11787853.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):819-26 [11830538.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39274-9 [12167657.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7690-9 [12400011.001]
  • [Cites] Mol Cancer Res. 2002 Nov;1(1):79-87 [12496371.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1037-42 [12651595.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Oncol Rep. 2004 Mar;11(3):605-11 [14767510.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1448-56 [14973554.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] J Cell Sci. 2004 Apr 15;117(Pt 10):2037-49 [15054110.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 6;320(4):1096-102 [15249202.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):312-9 [15297167.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):979-83 [15300251.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1674-81 [1551052.001]
  • [Cites] Science. 1994 Nov 4;266(5186):816-9 [7973638.001]
  • [Cites] Science. 1995 Apr 28;268(5210):567-9 [7536959.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2394-9 [7757992.001]
  • (PMID = 17146615.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106610-04; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / K08 CA106610-04; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / K08 CA106610
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ NIHMS147177; NLM/ PMC2755224
  •  go-up   go-down


53. Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB: Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol; 2010 May;49(4):520-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / drug therapy. Indoles / therapeutic use. Kidney Neoplasms / complications. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy / methods. Nephrectomy. Pyrroles / therapeutic use. Vena Cava, Inferior. Venous Thrombosis / etiology
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Disease Progression. Fatal Outcome. Humans. Liver Neoplasms / secondary. Middle Aged. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20105087.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


54. Sha D, He YJ: [Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma]. Ai Zheng; 2006 Feb;25(2):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma].
  • This study was to explore the correlations of VEGF, Flt-1 and KDR expression to clinical features and prognosis of nasopharyngeal carcinoma (NPC) patients.
  • VEGF expression was related to primary tumor site, lymph node metastasis, and clinical stage (P=0.04, P<0.01, P=0.02, respectively); KDR expression was related to primary tumor site (P=0.03); all of them were related to local recurrence and/or distal metastasis (P<0.01, P<0.01, P=0.01, respectively), and poor overall survival (P<0.01, P=0.01, P=0.03, respectively).
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Nasopharyngeal Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Female. Follow-Up Studies. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480593.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


55. Kim H, Oh BK, Roncalli M, Park C, Yoon SM, Yoo JE, Park YN: Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology; 2009 Sep;50(3):752-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large liver cell change in hepatitis B virus-related liver cirrhosis.
  • Large liver cell change (LLCC) refers to microscopic lesions often found in various chronic liver diseases; however, its nature is still controversial.
  • Thirty-four formalin-fixed and 19 fresh frozen hepatitis B virus (HBV)-related cirrhosis samples were examined for the presence of LLCC, small liver cell change (SLCC), and hepatocellular carcinoma (HCC).
  • The cell cycle checkpoint status (p21, p27, p16, Tp53), cell dynamics (proliferating cell nuclear antigen, Ki-67, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling, M30), DNA damage (gamma-H2AX [H2A histone family, member X]), telomere lengths, chromosomal instability (micronuclei index), and senescence-associated beta-galactosidase (SA-beta-Gal) activity were evaluated using an in situ approach and compared to those in normal liver (n = 5) and liver with chronic cholestasis (34 cases of hepatolithiasis and three cases of primary biliary cirrhosis).
  • In HBV-related cirrhosis, the p21, p27, and p16 cell cycle checkpoint markers were activated in normal-looking cirrhotic hepatocytes (NLCH), but diminished gradually from LLCC, SLCC, to HCC, with an increase in Tp53 expression.
  • In contrast, cholestatic LLCC showed retained expression of cell cycle checkpoint markers and decreased net cellular gain compared to adjacent normal-looking hepatocytes.
  • The characteristics of HBV-related LLCC are more consistent with dysplastic rather than merely reactive hepatocytes, whereas cholestatic LLCC more likely represents reactive change with more stringent cell cycle checkpoint control.
  • [MeSH-major] Hepatitis B, Chronic / pathology. Liver Cirrhosis / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis. Carcinoma, Hepatocellular / pathology. Cell Aging / physiology. Cell Cycle. Cell Proliferation. Cholestasis, Intrahepatic / metabolism. Cholestasis, Intrahepatic / pathology. Chromosomal Instability. DNA Damage. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Liver Neoplasms / pathology. Middle Aged. Telomere / chemistry. beta-Galactosidase / analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585549.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.23 / beta-Galactosidase
  •  go-up   go-down


56. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, Curley SA, Choti MA, Elias D: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol; 2007 Oct;14(10):2807-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.
  • BACKGROUND: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown.
  • The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver.
  • RESULTS: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7).
  • Treatment of primary SCC was chemotherapy +/- radiotherapy alone (n = 29), chemotherapy +/- radiotherapy + surgery (n = 15), or surgery alone (n = 8).
  • Factors associated with reduced DFS were liver tumor size > 5 cm (hazard ratio (HR) = 2.02) and positive surgical margin (HR = 2.33).
  • Long-term survival, however, can be achieved following surgical resection of SCC liver metastasis, especially in patients who present with limited metachronous disease amenable to margin negative resection.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / secondary. Electrocoagulation. Esophageal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prognosis. Retreatment. United States


57. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J: Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res; 2008 May 15;14(10):3060-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
  • The primary end point of this study was vaccine safety, with immunologic and clinical responses as secondary end points.
  • A patient with clear cell ovarian cancer and symptomatic ascites had a durable (18-month) clinical response radiographically and biochemically, and one breast cancer patient had a confirmed decrease of >20% in the size of large liver metastasis.
  • [MeSH-minor] Adjuvants, Immunologic / metabolism. Adjuvants, Immunologic / therapeutic use. Adult. Aged. Antigens, CD58 / immunology. Antigens, CD58 / therapeutic use. Antigens, CD80 / immunology. Antigens, CD80 / therapeutic use. Female. Genetic Vectors. Humans. Intercellular Adhesion Molecule-1 / immunology. Intercellular Adhesion Molecule-1 / therapeutic use. Male. Middle Aged. Pilot Projects. Vaccines, Synthetic / immunology. Vaccines, Synthetic / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5800-7 [10582702.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7985-94 [15520206.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):63-7 [15864588.001]
  • [Cites] J Exp Med. 2005 Dec 19;202(12):1691-701 [16365148.001]
  • [Cites] Cancer Immunol Immunother. 2005 Mar;54(3):254-64 [15372205.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):720-31 [15613691.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2862-8 [15591121.001]
  • [Cites] J Immunol. 2005 May 15;174(10):5994-6004 [15879092.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4430-6 [15958627.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87 [16467102.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1260-9 [16489082.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1259-71 [16636135.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3089-94 [16809734.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Nov;15(11):1395-410 [17040199.001]
  • [Cites] Expert Opin Biol Ther. 2007 Apr;7(4):543-54 [17373905.001]
  • [Cites] Vaccine. 2007 Sep 27;25 Suppl 2:B89-96 [17573164.001]
  • [Cites] Int J Cancer. 2000 Mar 15;85(6):829-38 [10709104.001]
  • [Cites] Surgery. 2000 Apr;127(4):383-9 [10776428.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1228-39 [10922408.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3964-73 [11099326.001]
  • [Cites] Cancer Immunol Immunother. 2000 Dec;49(10):517-29 [11129322.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):206-14 [11196163.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3689-97 [11325840.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1181-91 [11350882.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4497-505 [11389081.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809-14 [11427731.001]
  • [Cites] J Immunother. 2002 Mar-Apr;25(2):97-138 [12074049.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):109-17 [12242725.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3219-25 [12374692.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1837-49 [12738742.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s [12743133.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):6338-47 [12794167.001]
  • [Cites] Br J Radiol. 2004 Jan;77(913):74-5 [14988145.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):487-8 [15026475.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2139-49 [15041735.001]
  • [Cites] J Immunother. 2004 May-Jun;27(3):240-53 [15076142.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2122-32 [15169798.001]
  • [Cites] J Immunol. 1987 Aug 15;139(4):1113-9 [3038997.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3657-62 [1712245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1109-18 [8145033.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):982-90 [7629885.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1545-51 [8622070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10972-7 [8855293.001]
  • [Cites] Vaccine. 1997 Apr-May;15(6-7):759-68 [9178479.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4570-7 [9377571.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3363-73 [9531296.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2401-8 [9667257.001]
  • [Cites] BMC Immunol. 2005;6:17 [16026627.001]
  • (PMID = 18483372.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010425-09
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD58; 0 / Antigens, CD80; 0 / Cancer Vaccines; 0 / Carcinoembryonic Antigen; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Vaccines, Synthetic; 126547-89-5 / Intercellular Adhesion Molecule-1
  • [Other-IDs] NLM/ NIHMS106857; NLM/ PMC2673097
  •  go-up   go-down


58. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol; 2005 Jan 1;23(1):133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
  • PURPOSE: The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma.
  • PATIENTS AND METHODS: Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m(2) subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m(2) subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days 1 through 5 and 15 to 19 [maximum 28 doses]) every 12 weeks.
  • For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2.
  • CONCLUSION: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / drug therapy. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Metastasis. Recombinant Proteins. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6267-8; author reply 6268-9 [16135500.001]
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9 [16170190.001]
  • [ErratumIn] J Clin Oncol. 2005 Apr 20;23(12):2877
  • (PMID = 15625368.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


59. Hlavatá Z, Pazderová N, Povinec P, Paulíny P, Majidi A, Fiala P, Martanovic P, Sálek T: The value of 18-FDG PET/CT imaging in a patient with atypical metastatic colorectal cancer--case report: 18-FDG PET/CT in colorectal cancer. Klin Onkol; 2009;22(6):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung cancer, renal cell carcinoma and malignant melanoma have been reported as the most frequent primary tumours.
  • Diagnosis of muscle metastasis from other primary cancer sites is more than problematic.
  • CASE: In this paper we report a case of metastasis of colorectal cancer in a 44-year-old man who underwent left-sided hemicolectomy due to the tumour mass in his left colic flexure followed by liver metastasectomy and cryocautery of the non-resectable metastasis in the VII segment.
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099747.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Lekoubou Looti AZ, Kengne AP, Djientcheu Vde P, Kuate CT, Njamnshi AK: Patterns of non-traumatic myelopathies in Yaounde (Cameroon): a hospital based study. J Neurol Neurosurg Psychiatry; 2010 Jul;81(7):768-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aetiologies were dominated by primary and secondary spinal tumours (mainly prostate carcinoma, lymphoma and liver carcinoma) that each accounted for 24.5% of cases.
  • Other causes included spinal tuberculosis (12.9%), tropical spastic paraparesis (five positive for human T cell lymphotrophic virus (HTLV)-I and one for HTLV-II) (4.8%), spinal degenerative disease (4.1%), acute transverse myelitis (4.1%), HIV myelopathy (1.4%), vitamin B12 deficiency myelopathy and multiple sclerosis (0.7%).
  • Metastasis is a leading cause of spinal cord compression with liver carcinoma being more frequent than reported elsewhere.
  • [MeSH-minor] Adult. Anal Canal / pathology. Cameroon / epidemiology. Female. Hospitals. Humans. Infection / complications. Infection / epidemiology. Liver Neoplasms / complications. Liver Neoplasms / pathology. Male. Middle Aged. Neoplasm Metastasis. Paraplegia / etiology. Paraplegia / pathology. Quadriplegia / etiology. Quadriplegia / pathology. Sensation. Sex Factors. Spinal Cord Compression / complications. Spinal Cord Compression / pathology

  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581141.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Chamuleau RA, Deurholt T, Hoekstra R: Which are the right cells to be used in a bioartificial liver? Metab Brain Dis; 2005 Dec;20(4):327-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which are the right cells to be used in a bioartificial liver?
  • Because of the xenotransplantation-related disadvantages of porcine cells and the shortage of primary human hepatocytes, other sources of bio-components have to be explored.
  • The future lies in the development of one or more human hepatocyte cell lines, which will have minimal immunogenicity, no risk of xeno-zoonosis, and the requested functionality and availability.
  • Primary sources for the development of such human cell lines are liver-tumor-derived cell lines, immortalized fetal or adult hepatocytes, and stem cells of hepatic, hematopoietic, or embryonic origin.
  • At present the most promising results for BAL application have been obtained by immortalization of human fetal liver cells by reconstitution of telomerase activity.
  • However, in all cell types tested so far, the in vitro differentiation cannot be stimulated to such an extent that their functionality reaches that of primary human hepatocytes.
  • [MeSH-major] Liver / cytology. Liver, Artificial
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Fetus / cytology. Hematopoietic Stem Cells / physiology. Hepatocytes / physiology. Humans. Stem Cell Transplantation

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Oct 30;425(6961):968-73 [14555960.001]
  • [Cites] Cell Transplant. 2003;12(5):469-73 [12953920.001]
  • [Cites] Hepatology. 1996 Dec;24(6):1446-51 [8938179.001]
  • [Cites] Diabetes. 2004 Jan;53(1):105-12 [14693704.001]
  • [Cites] Surgery. 2002 Aug;132(2):384-90 [12219039.001]
  • [Cites] Fukuoka Igaku Zasshi. 2001 Aug;92(8):299-305 [11586514.001]
  • [Cites] Hepatology. 1989 Mar;9(3):367-72 [2563984.001]
  • [Cites] Int J Artif Organs. 1999 Nov;22(11):769-77 [10612305.001]
  • [Cites] Nat Med. 2004 Jan;10(1):55-63 [14702635.001]
  • [Cites] Science. 2000 Feb 18;287(5456):1258-62 [10678831.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11307-12 [11027332.001]
  • [Cites] Ann Surg. 2004 May;239(5):660-7; discussion 667-70 [15082970.001]
  • [Cites] Lancet. 2000 Aug 19;356(9230):621-7 [10968434.001]
  • [Cites] Mech Dev. 2003 Jan;120(1):117-30 [12490302.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1147-56 [15057753.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1229-34 [11062533.001]
  • [Cites] Int J Artif Organs. 2002 Oct;25(10):1001-5 [12456042.001]
  • [Cites] Liver Transpl. 2001 Jan;7(1):2-10 [11150414.001]
  • [Cites] Nat Med. 2004 Jul;10(7):744-8 [15195088.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):59-67 [8024360.001]
  • [Cites] Hepatology. 2000 Jul;32(1):11-6 [10869283.001]
  • [Cites] J Clin Invest. 2002 May;109(10):1291-302 [12021244.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):216-30 [15273544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jan;85(1):160-4 [2893372.001]
  • [Cites] Transplant Proc. 2001 Feb-Mar;33(1-2):1935 [11267578.001]
  • [Cites] Dev Dyn. 2004 Feb;229(2):243-58 [14745950.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):432-44 [12557149.001]
  • [Cites] ASAIO J. 1993 Jul-Sep;39(3):M242-6 [8268536.001]
  • [Cites] Int J Artif Organs. 1997 Aug;20(8):418-21 [9323503.001]
  • [Cites] Tissue Eng. 2004 Jul-Aug;10(7-8):1113-24 [15363168.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):897-901 [12665832.001]
  • [Cites] Science. 1999 May 14;284(5417):1168-70 [10325227.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1379-92 [9210627.001]
  • [Cites] Transplant Proc. 1997 Feb-Mar;29(1-2):964-5 [9123610.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):257 [10917519.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1891-900 [12806622.001]
  • [Cites] Cell Transplant. 2004;13(3):197-211 [15191158.001]
  • [Cites] Cell Transplant. 2001;10(4-5):429-33 [11549067.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):971-4 [11581665.001]
  • [Cites] Science. 1999 Aug 20;285(5431):1236-41 [10455044.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3639-44 [11904425.001]
  • [Cites] Int J Artif Organs. 2002 Mar;25(3):182-91 [11999190.001]
  • (PMID = 16382343.001).
  • [ISSN] 0885-7490
  • [Journal-full-title] Metabolic brain disease
  • [ISO-abbreviation] Metab Brain Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


63. Ceafalan L, Vidulescu C, Radu E, Regalia T, Popescu I, Pana M, Serghei L, Voiculescu B, Popescu LM: [Expression of stem cell markers on fetal and tumoral human liver cells in primary culture]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):96-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of stem cell markers on fetal and tumoral human liver cells in primary culture].
  • We have identified populations expressing these markers in both fetal and tumoral human liver by flow cytometry, using monoclonal antibodies against CD90, CD117, CD34, and HLA-DR.
  • In tumoral liver CD117+/CD90+ cells were found in decreasing number from the neoplastic (2.48 +/- 0.67) and peritumoral region (0.88 +/- 0.12) to the area of para-tumoral (normal) parenchyma (0.13 +/- 0.04).
  • Using the same markers on fetal liver cells we have also identified small populations of CD117+/CD90+ cells (0.28 +/- 0.07%) and CD117+/CD34+ cells (1.13 +/- 0.24%), presumably resident stem cells or hematopoietic stem cells.
  • Immunomagnetic negative separation was then performed on fetal liver cells using monoclonal antibodies against specific markers of hematopoietic lineages such as CD3, 14, 16, 19, 22, and CD56 to eliminate this population.
  • Isolation using appropriate markers and initiation of primary cultures is a first step to the therapeutic use of fetal stem cells and for the study of adult liver stem cells involvement in carcinogenesis.
  • [MeSH-major] Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / immunology. Fetus. Hepatocytes / immunology. Liver Neoplasms / immunology. Stem Cells
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antigens, Thy-1 / analysis. Flow Cytometry. HLA-DR Antigens / analysis. Humans. Immunomagnetic Separation. Microscopy, Fluorescence. Proto-Oncogene Proteins c-kit / analysis. Stem Cell Transplantation / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607835.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Thy-1; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


64. Suenaga M, Matsushita K, Kawamata N, Kukita T, Hamakawa Y, Gejima K, Onodera R, Sato T, Yamaguchi A, Inoue H, Arimura K, Arima N, Yoshida H, Tei C: True malignant histiocytosis with trisomy 9 following primary mediastinal germ cell tumor. Acta Haematol; 2006;116(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] True malignant histiocytosis with trisomy 9 following primary mediastinal germ cell tumor.
  • A diagnosis of mediastinal germ cell tumor, mixed type involving seminoma, immature teratoma and embryonal carcinoma, was made by transthoracic needle biopsy.
  • Examination of bone marrow revealed increased atypical large histiocytes (5.6%) with hemophagocytosis, and thus, hemophagocytic syndrome related to germ cell tumor was diagnosed.
  • Chemotherapies for germ cell tumor and hemophagocytic syndrome were performed without any improvement, and he died of diffuse alveolar damage.
  • Autopsy revealed diffuse infiltration of immature histiocytes with hemophagocytosis in the liver, spleen and bone marrow.
  • The atypical histiocytes were positive for CD68 and lysozyme and negative for lymphoid markers, and the diagnosis of true malignant histiocytosis associated with mediastinal germ cell tumor was made.
  • [MeSH-major] Chromosomes, Human, Pair 9. Histiocytic Sarcoma / pathology. Lymphohistiocytosis, Hemophagocytic / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Second Primary / pathology. Trisomy
  • [MeSH-minor] Adult. Antigens, CD. Antigens, Differentiation, Myelomonocytic. Biopsy, Needle. Bone Marrow / pathology. Histiocytes / pathology. Humans. Japan. Liver / pathology. Male. Muramidase. Pulmonary Alveoli / pathology. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809892.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


65. Andrle J, Schartinger VH, Schwentner I, Deibl M, Sprinzl GM: Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate? J Laryngol Otol; 2009 Aug;123(8):885-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate?
  • OBJECTIVES: The presence of distant metastases affects the therapeutic regime in patients with head and neck squamous cell carcinoma.
  • This study evaluated the necessity to undertake bone scanning, chest computed tomography and abdominal ultrasonography in patients presenting with primary advanced head and neck squamous cell carcinoma.
  • METHODS: One hundred and sixty-three patients with head and neck squamous cell carcinoma who were scheduled for major surgery underwent screening for distant metastases.
  • Only one patient with primary liver metastases was detected by abdominal ultrasonography; this patient also had pulmonary metastases.
  • CONCLUSIONS: Computed tomography of the thorax is the most important technique for screening patients with head and neck squamous cell carcinoma.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms. Lung Neoplasms / secondary. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone and Bones / radionuclide imaging. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies. Tomography, X-Ray Computed / methods


66. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • In asynchronous cases, being aware of this association can explain the absence of a second primary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Kuo FY, Swanson PE, Yeh MM: Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study. Am J Surg Pathol; 2009 Jan;33(1):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study.
  • BACKGROUND: Pancreatic acini-like tissue is occasionally seen in the liver.
  • To gain further insight into this issue, we performed a pathologic and immunohistochemical study in liver explants to identify pancreatic acinar tissue.
  • DESIGN: A total of 382 liver explants transplanted from 1995 to 2000 were examined.
  • RESULTS: Sixteen (4.2%) of 382 liver explants contained pancreatic acini-like tissue.
  • Fifteen of these were cirrhotic livers due to cryptogenic cirrhosis (n=1), primary biliary cirrhosis (n=3), primary sclerosing cholangitis (n=1), chronic hepatitis C-related cirrhosis (n=5), and cirrhosis with hepatitis C and hepatocellular carcinoma (n=5).
  • CONCLUSIONS: Our results collectively indicate that pancreatic acini-like tissue in liver represent aggregates of pancreatic acinar cells admixed with small intra-acinar terminal ductules.
  • [MeSH-major] Cell Transdifferentiation / physiology. Choristoma / etiology. Choristoma / pathology. Liver Diseases / pathology. Pancreas
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987542.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Granci V, Bibeau F, Kramar A, Boissière-Michot F, Thézénas S, Thirion A, Gongora C, Martineau P, Del Rio M, Ychou M: Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer; 2008 Oct;44(15):2312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drug resistance is believed to cause treatment failure in patients with metastatic colorectal carcinoma (CRC).
  • Resistance to chemotherapy can involve different processes, including apoptosis, whose extrinsic pathway is regulated by expression of death-inducing TRAIL-R1 and -R2 and inhibitory TRAIL-R3 and -R4 cell surface receptors.
  • We analysed TRAIL-R 1, -2, -3 and -4 expression by immuno-histochemistry in CRC, using tissue micro arrays, and found that concomitant low/medium TRAIL-R1 and high TRAIL-R3 expression in primary CRC is significantly associated with a poor response to 5-FU-based first-line chemotherapy and with shorter progression-free survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Disease Progression. Disease-Free Survival. Female. Fluorouracil / therapeutic use. GPI-Linked Proteins. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Proteins / metabolism. Prognosis. Treatment Outcome. Tumor Necrosis Factor Decoy Receptors / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755584.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10C protein, human; 0 / Tumor Necrosis Factor Decoy Receptors; U3P01618RT / Fluorouracil
  •  go-up   go-down


69. Nan KJ, Ruan ZP, Jing Z, Qin HX, Wang HY, Guo H, Xu R: Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis. World J Gastroenterol; 2005 Jan 14;11(2):228-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
  • AIM: To evaluate the expression of fragile histidine triad (FHIT) gene protein, product of a candidate tumor suppressor, and to investigate the relationship between FHIT, cell apoptosis and proliferation, and pathological features of primary hepatocellular carcinoma (HCC).
  • METHODS: Forty-seven HCC and ten normal liver specimens were collected during surgical operation between 2001 and 2003.
  • FHIT and proliferating cell nuclear antigen (PCNA) expression were detected by immunohistochemistry, and apoptotic level was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay on the tissue sections.
  • RESULTS: All normal liver tissues showed a strong expression of FHIT, whereas 28 of 47 (59.6%) carcinomas showed a significant loss or absence of FHIT expression (P = 0.001).
  • Apoptotic incidence in advanced TNM stage carcinoma and those with positive FHIT expression was higher than that in early stage carcinoma (P = 0.030) and in those with negative FHIT expression (P = 0.044) respectively.
  • The proliferating potential of hepatocellular carcinoma was associated with FHIT expression (P = 0.016) and the aggressive feature (P = 0.019).
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Apoptosis / genetics. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cell Division / genetics. Genes, Tumor Suppressor. Histidine / genetics. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Female. Humans. Liver / physiology. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Reference Values

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15633221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 4QD397987E / Histidine; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4205407
  •  go-up   go-down


70. Vitale A, D'Amico F, Gringeri E, Valmasoni M, Pauletto A, Bonsignore P, Bassi D, D'Amico FE, Polacco M, Burra P, Russo F, Angeli P, Poci C, Feltracco P, Romano A, Cillo U: Prognostic evaluation of the donor risk index among a prospective cohort of Italian patients undergoing liver transplantation. Transplant Proc; 2009 May;41(4):1096-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic evaluation of the donor risk index among a prospective cohort of Italian patients undergoing liver transplantation.
  • BACKGROUND/AIM: The definition of an extended criteria donor for orthotopic liver transplantation (OLT) remains controversial.
  • Recipient inclusion criteria were: adult patients with chronic liver disease enlisted for primary OLT.
  • The primary end point was the incidence of primary graft dysfunction (PDF), namely, aspartate aminotransferase (AST) >2000 U/mL and prothrombin time <40% on postoperative days 2-7.
  • Recipient characteristics are: age 55 years (range, 27-68); hepatocellular carcinoma in 36 subjects (49%); MELD was 16 (range, 7-39); and Child-Pugh score was 8 (range, 6-14).
  • In terms of the primary end points, the DRI did not provide a significant PDF predictor (P = .84).
  • Among all evaluated donor and recipient variables, the following were related to the incidence of graft PDF: donor age (P = .07), ultrasound signs of steatosis (P = .02), donor AST (P = .05), cell saver infusion (P = .07), and warm (P = .04) and cold ischemia (P = .07) times.
  • [MeSH-major] Donor Selection. Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Graft Survival. Humans. Liver Diseases / surgery. Male. Middle Aged. Prospective Studies. Retrospective Studies. Risk Assessment. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460490.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, Zheng L: High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol; 2009 Mar;40(3):381-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection.
  • This study attempted to investigate the prognostic values of tumor-infiltrating macrophages in patients with hepatocellular carcinoma after resection, paying particular attention to their tissue microlocalization.
  • The CD68(+) macrophages were assessed by immunohistochemistry in tissues from 137 patients with hepatocellular carcinoma.
  • Our results demonstrate that high macrophage infiltration predicts poor prognosis in patients with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Macrophages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Count. Cell Line, Tumor. Cell Movement. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992916.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


72. Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, Stief CG, Jauch KW, Bruns CJ: Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol; 2010 Aug;28(4):543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis.
  • The value of surgical resection of renal cell carcinoma (RCC) liver metastases still remains unclear.
  • OBJECTIVE: Of our study was to evaluate the efficacy of liver resection by comparing patients who could have undergone metastasectomy due to limited disease, but refused surgery.
  • MATERIALS AND METHODS: Eighty-eight patients were identified with liver metastases and indication of surgery between 1995 and 2006.
  • In 68 patients, liver resection was performed, 20 patients denied surgery and served as comparison group.
  • Median amount of liver metastases was 2 (range 1-30).
  • Low-grade primary RCC had a MS of 155 (95% CI 123-187) months compared to 29 (95% CI 8-50) months without resection (P = 0.0036).
  • CONCLUSIONS: Liver metastasectomy is an independent valuable tool in the treatment of metastatic RCC and significantly prolongs patient's survival, even if further systemic treatment is necessary.
  • With the evidence given, patients may benefit from liver metastasis resection if technically feasible.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Liver / surgery. Liver Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Databases, Factual. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Young Adult


73. Zhang Y, Li W, Vore M: Translational regulation of rat multidrug resistance-associated protein 2 expression is mediated by upstream open reading frames in the 5' untranslated region. Mol Pharmacol; 2007 Jan;71(1):377-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ribonuclease protection assays demonstrated that transcription of the Mrp2 gene at the various initiation sites was tissue-specific, with the major initiation site in the liver and kidney being -98 and -132 nucleotides, respectively.
  • In the jejunum, the primary and secondary initiation sites were -98 and -132 nucleotides, respectively, with the converse true in the ileum.
  • The relative abundance of these Mrp2 transcripts expressed in tissues varied with age from birth to the adult.
  • [MeSH-minor] Animals. Base Sequence. Carcinoma, Hepatocellular. Cell Line, Tumor. DNA Primers. DNA, Complementary / genetics. Humans. Liver Neoplasms. Molecular Sequence Data. Polymerase Chain Reaction. RNA, Messenger / genetics. Rats. Transcription, Genetic. Uridine Triphosphate / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065236.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM55343
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / ATP-Binding Cassette Transporters; 0 / Abcc2 protein, rat; 0 / DNA Primers; 0 / DNA, Complementary; 0 / RNA, Messenger; UT0S826Z60 / Uridine Triphosphate
  •  go-up   go-down


74. Cioppa T, Marrelli D, Neri A, Caruso S, Pedrazzani C, Malagnino V, Pinto E, Roviello F: A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy. Eur J Cancer Care (Engl); 2007 Sep;16(5):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy.
  • Primary small-cell carcinoma (SmCC) of the stomach is a rare neoplasm with a poor prognosis and unclear histogenesis: to date, only 50 cases, including ours, have been reported in the literature.
  • In this paper, the authors present a clinical case and the surgical treatment of an adult with a SmCC of the stomach associated with gastric adenocarcinoma.
  • After laparotomy, a large neoplasm with locoregional extension and multiple liver metastases were found.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / secondary. Kidney Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760934.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Qin XT, Lu Y, Chen XQ, Xu HP, Fan HJ: [Correlation of hepatitis B virus infection to non-Hodgkin's lymphoma]. Ai Zheng; 2007 Mar;26(3):294-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Previous studies showed that the infection rate of hepatitis B virus (HBV) is higher in non-Hodgkin's lymphoma (NHL) patients than in non-primary liver cancer solid tumor patients and general population in the same region, but the correlation of HBV infection to NHL is inconclusive.
  • This study was to compare HBV infection rate of NHL patients with that of non-primary liver cancer solid tumor patients, and explore the correlation of HBV infection to NHL.
  • METHODS: The infection of hepatitis B virus surface antigen (HBsAg) in 109 NHL patients and 128 colorectal carcinoma patients was detected.
  • RESULTS: The positive rate of HBsAg was significantly higher in NHL patients than in colorectal carcinoma patients and general population (40.4% vs. 14.1% and 17.3%, P<0.01).
  • Regarding colorectal carcinoma patients as a reference group, odds ratio (OR) of NHL in HbsAg-positive population was 2.87, and the 95% confidence interval (95% CI) was 1.830-4.502.
  • CONCLUSION: The positive rate of HBsAg is higher in NHL patients than in colorectal carcinoma patients and general population.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Confidence Intervals. Female. Hepatitis B / immunology. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / virology. Male. Odds Ratio. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355794.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


76. Perera GK, Child FJ, Heaton N, O'Grady J, Higgins EM: Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol; 2006 May;154(5):868-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients.
  • OBJECTIVES: The primary objective was to determine the different types of cutaneous lesions encountered in the adult liver transplant population.
  • METHODS: Two dermatologists examined 100 consecutive liver transplant recipients (LTRs) attending the transplant outpatient department.
  • Four patients developed skin cancers; among them there were a total of seven skin cancers (one squamous cell carcinoma, six basal cell carcinomas).
  • The relatively low prevalence of skin cancer in our liver transplant population may in part be explained by the relatively high percentage of recipients on dual and monotherapy (48% and 17% respectively), and the shorter duration of therapy.
  • [MeSH-major] Liver Transplantation / immunology. Skin Diseases / etiology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Keratosis / etiology. Keratosis / immunology. Liver Failure / etiology. Liver Failure / surgery. Male. Middle Aged. Risk Factors. Skin Diseases, Infectious / etiology. Skin Diseases, Infectious / immunology. Skin Neoplasms / etiology. Skin Neoplasms / immunology. Sunlight / adverse effects

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634888.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


77. Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation: A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst; 2008 Apr 16;100(8):533-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
  • A randomized trial was performed to test the impact of such dose intensification on the long-term survival of patients with small cell lung cancer (SCLC).
  • The primary outcome was 3-year survival.
  • Comparisons between response rates and toxic effects within subgroups (limited or extensive disease, liver metastases or no liver metastases, Eastern Cooperative Oncology Group performance status of 0 or 1, normal or abnormal lactate dehydrogenase levels) were also performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Incidence. Male. Middle Aged. Odds Ratio. Prognosis. Research Design. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2009 Jan 7;101(1):67; author reply 67-8 [19116385.001]
  • [CommentIn] J Natl Cancer Inst. 2008 Apr 16;100(8):520-1 [18398099.001]
  • (PMID = 18398095.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  • [Investigator] Aversa S; Brunsvig P; Buxhofer V; Crown J; De Bock R; Demirer T; Kühr T; Lange A; Leyvraz S; Martinelli G; Montes A; Piazza E; Ploner F; Rosti G; Rudolf C; Schneider CP; van Klaveren R; Yilmaz U; Parmar M; Thatcher N; Hansen H
  •  go-up   go-down


78. Tanioka M, Katsumata N, Sasajima Y, Ikeda S, Kato T, Onda T, Kasamatsu T, Fujiwara Y: Clinical characteristics and outcomes of women with stage IV endometrial cancer. Med Oncol; 2010 Dec;27(4):1371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neither surgery as primary therapy nor optimal cytoreduction was significantly related to overall survival in either the 28 patients in whom stage IV was diagnosed preoperatively or in all 41 patients.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Neoplasm, Residual / surgery
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):4-9 [14751130.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):85-91 [10926785.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):285-91 [17688923.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):448-53 [12366661.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):325-33 [17532033.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):10-4 [14751131.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):133-8 [15385122.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):345-52 [15099944.001]
  • (PMID = 20024630.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Gao WQ, Zhou XJ, Bai X, Su J, Ruan CG: [Clinical significance of the dysregulated expression of von Willebrand factor-cleaving protease in patients with primary hepatocarcinoma]. Zhonghua Gan Zang Bing Za Zhi; 2005 Oct;13(10):795-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of the dysregulated expression of von Willebrand factor-cleaving protease in patients with primary hepatocarcinoma].
  • [MeSH-major] ADAM Proteins / biosynthesis. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. von Willebrand Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Line. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16248961.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / von Willebrand Factor; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAMTS13 protein, human
  •  go-up   go-down


80. Chen B, Gao L, Xu GZ, Li SY, Huang XD, Yi JL: [Postoperative radiotherapy for primary intraosseous carcinoma of the jaws]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):540-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative radiotherapy for primary intraosseous carcinoma of the jaws].
  • OBJECTIVE: To investigate the indication, location and dose of postoperative radiotherapy for primary intraosseous carcinoma (PIOC) of the jaws.
  • It seemed that surgery plus postoperative radiotherapy could not improve the survival of PIOC patients with involvement of adjacent soft-tissues or positive neck nodes or partial excision of primary tumor when compared with surgery alone, if the bias of selection in the patients for postoperative radiotherapy was neglected.
  • CONCLUSION: Postopreative radiotherapy may improve the survival for the patient with primary intraosseous carcinoma of the jaws.
  • Our suggestion is that postoperative radiotherapy should be applied to the patient with any of the following items: positive operative margin; tumor involvement of adjacent soft-tissues; positive neck nodes; partial excision of primary tumor.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mandibular Neoplasms / radiotherapy. Maxillary Neoplasms / radiotherapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Mandible / surgery. Maxilla / surgery. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


81. Moghimi-Dehkordi B, Safaee A, Ghiasi S, Zali MR: Survival in gastric cancer patients: univariate and multivariate analysis. East Afr J Public Health; 2009 Apr;6 Suppl(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Retrospective study of overall patients diagnosed with gastric cancer registered in the cancer registry center of Research Center for Gastroenterology and Liver Disease (RCGLD), Shahid Beheshti University, M.C, Tehran, Iran, between Dec.
  • CONCLUSIONS: According to results, early detection of cancer in lower ages and in primary grades of tumor is important to increase patient's life expectancy.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Signet Ring Cell / mortality. Stomach Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Iran / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084985.001).
  • [ISSN] 0856-8960
  • [Journal-full-title] East African journal of public health
  • [ISO-abbreviation] East Afr J Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tanzania
  •  go-up   go-down


82. Agarwal R, Levinson AW, Schowinsky J, Su LM: Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma. Urology; 2007 Nov;70(5):1008.e17-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma.
  • We report the case of a 39-year-old woman with a large right renal mass 20 cm in size with heterogeneous solid and cystic components as well as concurrent liver lesions suspicious for metastatic renal cell carcinoma.
  • Surgical extirpation of the renal mass and liver lesions was performed laparoscopically with the pathological analysis revealing a rare renal neoplasm--mixed epithelial and stromal tumor of the kidney--and adenomas of the liver.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


83. Chahal P, Baron TH, Poterucha JJ, Rosen CB: Endoscopic retrograde cholangiography in post-orthotopic liver transplant population with Roux-en-Y biliary reconstruction. Liver Transpl; 2007 Aug;13(8):1168-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic retrograde cholangiography in post-orthotopic liver transplant population with Roux-en-Y biliary reconstruction.
  • Its effectiveness in post-orthotopic liver transplantation (OLT) patients with Roux-en-Y biliary reconstruction has not been reported.
  • The indication for liver transplant was end-stage liver disease or occurrence of cholangiocarcinoma from primary sclerosing cholangitis in 28 patients and a case each of chronic hepatitis C, alcoholic liver disease, and metastatic islet cell carcinoma.
  • ERC indications were both diagnostic and therapeutic and included the following: evaluation of increased liver biochemistries and fever in 12 patients, dilation of anastomotic biliary strictures in 10 patients, removal of fractured biliary tube or retained biliary stent in 6 patients, and in 1 patient each, biliary stone removal, management of bile leak, and jejunal tube extension placement for nutritional purpose.
  • [MeSH-major] Anastomosis, Roux-en-Y / methods. Biliary Tract Diseases / surgery. Biliary Tract Diseases / therapy. Biliary Tract Surgical Procedures / methods. Cholangiography / methods. Endoscopy / methods. Liver Transplantation / methods. Reconstructive Surgical Procedures
  • [MeSH-minor] Adolescent. Adult. Aged. Bile Duct Diseases / surgery. Bile Duct Diseases / therapy. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 AASLD.
  • (PMID = 17663414.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. West J, Wood H, Logan RF, Quinn M, Aithal GP: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer; 2006 Jun 5;94(11):1751-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001.
  • In the last two decades, mortality from primary liver cancer has increased in the UK.
  • We calculated directly age-standardised incidence rates (using the European standard population) by subsite and histological type for all cancers of the liver, gallbladder and biliary tract in England and Wales from 1971 to 2001, using cancer registry data.
  • The incidence of cancers of the liver, gallbladder and biliary tract increased, with the greatest rise, around 12-fold, in intrahepatic bile duct cancers.
  • The rate of liver cell cancer increased by around 45% in males, but by <10% in females.
  • Cholangiocarcinoma increased around 16-fold and became the most common type of primary liver cancer in females, while hepatocellular carcinoma remained the commonest type in males.
  • The age-specific incidence rates showed that intrahepatic bile duct cancer continued to increase throughout the 1990s in those aged 75 and over, while liver cell cancer decreased in the older age groups.
  • In conclusion, there were increases in the incidence of primary liver cancer, which have been particularly dramatic for intrahepatic bile duct cancer, over the last three decades of the 20th century in England and Wales.
  • [MeSH-major] Biliary Tract Neoplasms / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. England / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Registries. Sex Characteristics. Wales / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2005 Apr;54(4):533-9 [15753540.001]
  • [Cites] Health Stat Q. 2004 Autumn;(23):7-17 [15704380.001]
  • [Cites] Gut. 2001 Jun;48(6):816-20 [11358902.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • [Cites] Gut. 1989 May;30(5):695-700 [2731765.001]
  • [Cites] Popul Trends. 1996 Winter;(86):29-35 [8987096.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1142-3 [9343506.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] Gastrointest Endosc. 1988 May-Jun;34(3):277-8 [3292346.001]
  • (PMID = 16736026.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361300
  •  go-up   go-down


85. Paret C, Hildebrand D, Weitz J, Kopp-Schneider A, Kuhn A, Beer A, Hautmann R, Zöller M: C4.4A as a candidate marker in the diagnosis of colorectal cancer. Br J Cancer; 2007 Oct 22;97(8):1146-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, tumour cell lines released C4.4A by vesicle shedding and proteolytic cleavage.
  • C4.4A was expressed in over 80% of primary colorectal cancer and liver metastasis with negligible expression in adjacent colonic mucosa, inflamed colonic tissue and liver.
  • C4.4A expression was only observed in about 50% of pancreatic cancer and renal cell carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Adhesion Molecules / metabolism. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Flow Cytometry. GPI-Linked Proteins. Humans. Immunohistochemistry. Immunoprecipitation. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1992 Sep 1;208(2):397-404 [1325906.001]
  • [Cites] Int J Cancer. 1993 Feb 20;53(4):651-6 [8436439.001]
  • [Cites] FEBS Lett. 1994 Aug 1;349(2):163-8 [8050560.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):20807-10 [8063692.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32380-8 [7528215.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2818-26 [7773932.001]
  • [Cites] Clin Exp Metastasis. 1995 Jul;13(4):277-86 [7606890.001]
  • [Cites] Cell Growth Differ. 1996 May;7(5):663-78 [8732676.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):867-72 [9291807.001]
  • [Cites] Clin Chem. 1997 Oct;43(10):1868-76 [9342006.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):118-23 [9450571.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1843-9 [9581823.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):461-74 [10480338.001]
  • [Cites] Eur J Biochem. 1999 Sep;264(2):281-6 [10491072.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):89-104 [10508858.001]
  • [Cites] Thromb Haemost. 2005 Feb;93(2):192-8 [15711732.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2840-52 [15837731.001]
  • [Cites] Int J Cancer. 2005 Jul 10;115(5):724-33 [15729693.001]
  • [Cites] Oncol Rep. 2005 Sep;14(3):777-82 [16077991.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):3117-21 [16080575.001]
  • [Cites] Clin Exp Metastasis. 2005;22(1):11-24 [16132574.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2210-9 [16331622.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2135-47 [17278103.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1263-72 [17237151.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2584-8 [10825125.001]
  • [Cites] FEBS Lett. 2000 Jun 9;475(1):52-6 [10854857.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):400-5 [11196194.001]
  • [Cites] Gene. 2001 Jan 10;262(1-2):35-41 [11179665.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):344-7 [11180013.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1678-85 [11245483.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27982-90 [12034711.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):579-85 [12592373.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1849-58 [12673710.001]
  • [Cites] Mod Pathol. 2003 May;16(5):491-504 [12748256.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4):320-6 [14508099.001]
  • [Cites] Exp Dermatol. 2003 Oct;12(5):537-45 [14705793.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Biochem J. 2004 Jun 15;380(Pt 3):845-57 [15012588.001]
  • [Cites] Br J Cancer. 1978 Jan;37(1):61-6 [619957.001]
  • [Cites] Cancer Res. 1981 Feb;41(2):405-9 [7448785.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1294-9 [2917359.001]
  • [Cites] Hybridoma. 1989 Aug;8(4):481-91 [2777278.001]
  • [Cites] Dev Biol (N Y 1985). 1986;3:33-57 [3077969.001]
  • [Cites] Blood. 1991 Jul 15;78(2):264-76 [2070064.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):1989-2002 [9788443.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):362-71 [10197444.001]
  • [Cites] Prostate. 1999 May;39(2):123-9 [10221568.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):869-74 [10340907.001]
  • [Cites] EMBO J. 1999 Jun 1;18(11):3013-23 [10357814.001]
  • [Cites] Int J Oncol. 1999 Jul;15(1):143-8 [10375607.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):225-35 [10395292.001]
  • (PMID = 17912244.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / LYPD3 protein, human
  • [Other-IDs] NLM/ PMC2360445
  •  go-up   go-down


86. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N, Yanagihara K, Yokozaki H: High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch; 2007 Mar;450(3):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phosphatase of regenerating liver (PRL)-3, encoding a 22-kD low molecular weight tyrosine phosphatase, has been reported to be associated with metastasis of colorectal carcinoma.
  • We assessed the levels of PRL-3 mRNA expression to know whether its up-regulation was involved in progression and metastasis of gastric carcinoma.
  • High PRL-3 expression was detected in 36.2% of primary gastric carcinoma (with nodal metastasis, 55.6%; without nodal metastasis, 10%; P < 0.001) and in 74.1% of lymph node metastases.
  • The incidence of high PRL-3 expression in lymph node metastasis was significantly higher than in primary tumors (P < 0.044).
  • These results suggest that high PRL-3 expression may participate in the progression and metastasis of gastric carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Nodes. Male. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Neoplasm Staging. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Ther. 2002 Feb-Mar;93(2-3):307-17 [12191622.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8 [11355880.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Int Rev Cytol. 2001;204:49-95 [11243597.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Hybrid Hybridomics. 2004 Feb;23(1):23-7 [15000845.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(8):2444-8 [3162770.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3824-31 [12473596.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21444-52 [10747914.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Ann Surg. 1978 Dec;188(6):711-5 [736648.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Br J Surg. 1970 Dec;57(12):877-83 [5487028.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [Cites] J Histochem Cytochem. 1993 Apr;41(4):499-506 [8095509.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] FEBS Lett. 2004 May 7;565(1-3):181-7 [15135076.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):201-11 [14643450.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):381-90 [1986233.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • (PMID = 17235563.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


87. Zhong XG, He S, Yin W, Deng JY, Chen B: [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro]. Zhonghua Gan Zang Bing Za Zhi; 2005 Sep;13(9):644-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro].
  • OBJECTIVE: To explore the biological behavior of adult liver stem cells in a co-cultured system of them with hepatocellular carcinoma (HCC) cells without direct contact between the two kinds of cells.
  • METHODS: WB-F344, a kind of rat adult liver stem cell, and rat embryonic fibroblasts (REF) from a primary culture were engineered to express enhanced green fluorescent protein (EGFP) by recombinant adenoviral-mediated methods.
  • After the HCC cells grew to 40%-60% confluence in the culture dish with a 10-mm cell-free area, a similar number of WB-EGFP and REF-EGFP were placed in the blank areas respectively.
  • Their appearance was found not only when WB-EGFP cells were seeded into the cell-free area at the center of the dish, but also when seeded into the blank area at the extreme edge of the plate.
  • CONCLUSIONS: The results mean that adult liver stem cells have a biological behavior of selective tropism toward HCC cells in vitro, and suggest a possibility of using migratory liver stem cells as a delivery vehicle for gene therapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / cytology. Liver Neoplasms / pathology. Stem Cells / cytology

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174449.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Shah I, Sefvan O, Luqman U, Ibrahim W, Mehmood S, Alamgir W: Clinical stage of oral cancer patients at the time of initial diagnosis. J Ayub Med Coll Abbottabad; 2010 Jul-Sep;22(3):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Squamous cell carcinoma is the most common oral cancer.
  • OPG and CT scans of the head and neck region, chest X-rays, abdominal ultrasounds and liver function tests.
  • Size of the primary tumour, the size, number and laterality of the involved cervical lymph nodes and the presence/absence of distant metastases were documented and statistically analysed using SPSS-17.
  • The primary tumour was 4 Cm or more in size, (T3/T4) 71.25% of the cases.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Imaging. Female. Humans. Liver Function Tests. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Retrospective Studies

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22338419.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


89. Chalermchai T, Suwanrusme H, Chantranuwat P, Voravud N, Sriuranpong V: Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005. Asia Pac J Clin Oncol; 2010 Jun;6(2):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005.
  • OBJECTIVE: The aim of this study was to review cases of extra-pulmonary small cell carcinoma (EPSCC), including their clinical manifestations and treatment outcomes.
  • The most common primary sites were the gastrointestinal organs and the nasal cavity.
  • EPSCC of pancreas demonstrated a favorable clinical outcome with treatment, whereas primary EPSCC of the liver, esophagus and rectum had an aggressive natural history and a poor response to treatment.
  • CONCLUSION: Our report suggests that EPSCC may have a different biology from that of pulmonary small cell carcinoma.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / pathology. Urogenital Neoplasms / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20565423.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Number-of-references] 15
  •  go-up   go-down


90. Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F: Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol; 2009 Feb;50(2):323-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.
  • BACKGROUND/AIMS: Aberrant c-Jun N-terminal kinase (JNK) activation has been linked to hepatocellular carcinoma (HCC) in mouse models.
  • METHODS: The JNK activation, global gene expression, and the status of histone H3 methylations were measured in 31 primary human hepatocellular carcinoma (HCC) samples paired with the adjacent non-cancerous (ANC) tissues.
  • In addition, an association of JNK1 activation with the histone H3 lysines 4 and 9 tri-methylation was observed in the HCC tissues, which leads to an elevated expression of genes regulating cell growth and a decreased expression of the genes for cell differentiation and the p450 family members in HCC.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041150.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R01CA116697; United States / NCI NIH HHS / CA / R01 CA119028; United States / NCI NIH HHS / CA / R01 CA116697; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / 5R01CA119028
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Histones; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 8
  • [Other-IDs] NLM/ NIHMS546011; NLM/ PMC4417500
  •  go-up   go-down


91. Hameed O, Xu H, Saddeghi S, Maluf H: Hepatoid carcinoma of the pancreas: a case report and literature review of a heterogeneous group of tumors. Am J Surg Pathol; 2007 Jan;31(1):146-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid carcinoma of the pancreas: a case report and literature review of a heterogeneous group of tumors.
  • Hepatoid carcinomas are tumors that display, at least focally, cytologic and/or architectural features of hepatocellular carcinoma.
  • We report a case of hepatoid carcinoma of the pancreas that developed in a 41-year-old woman in association with a pancreatic endocrine carcinoma.
  • The excised specimen displayed a poorly differentiated pancreatic endocrine carcinoma associated with well-defined islands of larger tumor cells growing in a perisinusoidal pattern which, based on their immunohistochemical profile and the demonstration of bile, proved to represent a hepatoid component.
  • This case and prior examples in the literature suggest that hepatoid carcinomas of the pancreas appear to be a heterogeneous group of tumors (pure or associated with another histologic component) that are often associated with early liver metastasis and a short survival, although those arising as a component of endocrine tumors seem to fare slightly better.
  • Hepatoid carcinoma of the pancreas should be included in the differential diagnosis of pancreatic tumors composed of large eosinophilic cells.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Islet Cell / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197931.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


92. Cui Y, Bi M, Su T, Liu H, Lu SH: Molecular cloning and characterization of a novel esophageal cancer related gene. Int J Oncol; 2010 Dec;37(6):1521-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulse-chase experiments showed that ECRG2 protein was detected in both cell lysates and culture medium, indicating that the ECRG2 protein was extracellularly secreted after the post-translational cleavage.
  • Northern blot analysis revealed the presence of the major band corresponding to a size of 569 kb throughout the fetal skin, thymus, esophagus, brain, lung, heart, stomach, liver, spleen, colon, kidney, testis, muscle, cholecyst tissues and adult esophageal mucosa, brain, thyroid tissue and mouth epithelia.
  • However, ECRG2 gene was significantly down-regulated in primary esophageal cancer tissues.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Proteinase Inhibitory Proteins, Secretory / genetics
  • [MeSH-minor] Adult. Amino Acid Sequence. Base Sequence. Chromosome Mapping. Cloning, Molecular. Computational Biology. DNA, Complementary / analysis. DNA, Complementary / isolation & purification. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Models, Molecular. Molecular Sequence Data. Neoplasm Invasiveness. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042721.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human
  •  go-up   go-down


93. Choi HN, Kim KR, Lee JH, Park HS, Jang KY, Chung MJ, Hwang SE, Yu HC, Moon WS: Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol Rep; 2009 Jan;21(1):57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
  • Serum response factor (SRF) is a transcription factor that controls cell growth, differentiation, and tumor progression as well as muscle development and function.
  • Reduced expression of cell adhesion molecules has been reported to be associated with tumor metastasis.
  • The aim of this study was to evaluate the expression and a role of SRF in liver metastasis of primary colorectal carcinomas.
  • We examined the expression of SRF, E-cadherin, and beta-catenin by the use of immunochemical staining in 43 cases as a set of primary colorectal carcinomas and liver metastases.
  • We also examined the role of SRF in colorectal carcinoma by overexpression of SRF in a colon cancer cell line.
  • In metastatic carcinoma surgical samples, there was a marked increased expression of SRF as compared to expression in primary colorectal carcinoma surgical samples (P<0.05).
  • E-cadherin expression was significantly decreased in metastatic liver carcinoma samples as compared to primary colorectal carcinoma samples (P<0.001).
  • Frequent nuclear translocation of beta-catenin protein in primary and metastatic carcinoma cells was observed.
  • Overexpression of SRF in colorectal carcinoma cells enhanced cell motility and invasiveness.
  • These results indicate that overexpression of SRF in colorectal carcinoma cells is associated with modulation of E-cadherin/beta-catenin expression and may play an important role in colorectal cancer metastasis.
  • [MeSH-major] Cadherins / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Serum Response Factor / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Middle Aged. Transfection

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082443.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Serum Response Factor; 0 / beta Catenin
  •  go-up   go-down


94. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS: Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res; 2009;28:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the most common tumor in the adult liver, with high relapse and mortality rates despite diverse treatment modalities.
  • METHODS: Frozen tumors and non-cancerous surrounding tissues from 120 patients with primary HCC were studied.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. Nicotinamide N-Methyltransferase / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cohort Studies. Disease-Free Survival. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1991 Nov;82(11):1277-83 [1836457.001]
  • [Cites] Clin Chim Acta. 1990 Jan 31;186(3):359-74 [2311261.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14835-40 [8182091.001]
  • [Cites] J Hepatol. 1994 Jan;20(1):138-42 [8201215.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Oncol Res. 2004;14(10):491-9 [15559763.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):527-39 [15486044.001]
  • [Cites] J Pathol. 2005 Feb;205(3):377-87 [15682440.001]
  • [Cites] Toxicol Pathol. 2005;33(1):175-80 [15805069.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] J Urol. 2006 Nov;176(5):2248-54 [17070307.001]
  • [Cites] Exp Mol Med. 2006 Oct 31;38(5):455-65 [17079861.001]
  • [Cites] BMC Bioinformatics. 2007;8:66 [17326819.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 May;134(5):551-9 [17922140.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4814-20 [18676753.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6679-89 [18724390.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9167-75 [19010888.001]
  • [Cites] Physiol Genomics. 2001 Feb 7;5(1):21-33 [11161003.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4568-75 [11494152.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Feb;61(2):111-24 [11853016.001]
  • [Cites] Hepatology. 2002 May;35(5):1237-46 [11981774.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3939-44 [12124323.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] Neurosci Lett. 2003 May 15;342(1-2):13-6 [12727306.001]
  • [Cites] Curr Mol Med. 2003 Sep;3(6):573-88 [14527088.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4990-6 [14557485.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):129-37 [15324696.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5 [15508103.001]
  • [Cites] Gastroenterology. 1981 Oct;81(4):668-75 [7262512.001]
  • [Cites] Hepatology. 1988 Jan-Feb;8(1):65-8 [3338721.001]
  • [Cites] Arch Biochem Biophys. 1988 Feb 1;260(2):601-8 [2963591.001]
  • [Cites] Tumour Biol. 1994;15(1):7-16 [8146531.001]
  • (PMID = 19216803.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.1.1.1 / NNMT protein, human; EC 2.1.1.1 / Nicotinamide N-Methyltransferase
  • [Other-IDs] NLM/ PMC2657806
  •  go-up   go-down


95. Turato C, Ruvoletto MG, Biasiolo A, Quarta S, Tono N, Bernardinello E, Beneduce L, Fassina G, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P: Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Dig Liver Dis; 2009 Mar;41(3):212-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease.
  • BACKGROUND: The serpin squamous cell carcinoma antigen (SCCA, SERPINB3) has been found over-expressed in primary liver cancer and at lower extent in cirrhosis and chronic hepatitis.
  • AIM: To explore SCCA-1 polymorphism in patients with HCV infection as single etiologic factor and different extent of liver disease.
  • CONCLUSIONS: The newly identified SCCA-PD variant was more frequently found in liver cirrhosis, suggesting that patients carrying this polymorphism are more prone to develop progressive liver fibrosis.
  • [MeSH-major] Antigens, Neoplasm / genetics. Liver Diseases / genetics. Polymorphism, Restriction Fragment Length. Serpins / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Chronic Disease. Female. Humans. Immunoglobulin M / blood. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657489.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin M; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


96. Lin GH, Wang J, Li SH, Wang J, Xu L, Li SP: Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. Chin J Cancer; 2010 Apr;29(4):403-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma.
  • BACKGROUND AND OBJECTIVE: There are few studies about origins of regulatory T (Treg) cells increased in primary hepatocellular carcinoma (HCC) tissue.
  • Studies showed that Treg cells could be induced by transforming growth factor-beta1 (TGF-beta1), but the relation between TGF-beta1 expression and Treg cell infiltration is unclear in HCC tissue.
  • METHODS: Envision immunohistochemistry was used to detect the expression of TGF-beta1 and Foxp3 in 102 specimens of HCC tissue and paired adjacent non-tumor liver tissue.
  • Average Foxp3+ cell density in HCC was 2.98 cells/HP, but there was very few or no expression of Foxp3 in adjacent non-tumor liver tissue.
  • TGF-beta1 and Foxp3 expression had no correlations with tumor diameter, tumor capsule, liver cirrhosis, and so on.
  • The 5-year survival rate was not different between HCC tissues with high and low TGF-beta1 expression (P = 0.790); however, it was significantly lower in HCC tissues with high Treg cell infiltration than in those low infiltration (25% vs. 44%, P = 0.007).
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms. T-Lymphocytes, Regulatory / pathology. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Forkhead Transcription Factors / metabolism. Humans. Lymphocyte Count. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Survival Rate. Young Adult. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346216.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / alpha-Fetoproteins
  •  go-up   go-down


97. Zoller H, McFarlane I, Theurl I, Stadlmann S, Nemeth E, Oxley D, Ganz T, Halsall DJ, Cox TM, Vogel W: Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology; 2005 Aug;42(2):466-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease.
  • In the index case, the disorder is characterized by abundant deposition of hemosiderin in all tissues investigated (mesenteric lymph node, liver, gastric and duodenal mucosa, and also in squamous cell carcinoma of the lung).
  • Despite a significant burden of iron, no features of chronic liver disease were found in affected members of the family, including individuals aged up to 80 years.
  • In conclusion, the systemic iron burden in ferroportin disease is not a sufficient cause for chronic liver disease.
  • In patients with most, but not all, ferroportin mutations, retention of iron in macrophages of the liver and other organs may protect against damage to parenchymal cells.
  • [MeSH-minor] Adolescent. Adult. Aged. Ferritins / blood. Hepcidins. Humans. Liver / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Iron Overload.
  • MedlinePlus Health Information. consumer health - Hemochromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986403.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Cation Transport Proteins; 0 / HAMP protein, human; 0 / Hepcidins; 0 / Protein Precursors; 0 / metal transporting protein 1; 9007-73-2 / Ferritins
  •  go-up   go-down


98. Lin ZY, Chuang WL, Chuang YH, Yu ML, Hsieh MY, Wang LY, Tsai JF: Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. J Gastroenterol Hepatol; 2006 Feb;21(2):398-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
  • BACKGROUND: The purpose of this prospective study was to investigate whether amphotericin B (AmB) had any potential role in the systemic chemotherapy of primary hepatic malignancy using cancer cells collected by the authors' method of primary culture.
  • METHODS: The specimens obtained by ultrasound-guided fine-needle aspiration biopsy (22 G) from 15 patients with hepatocellular carcinoma (HCC) and one with cholangiocarcinoma were plated into culture flask without disaggregation by trypsin-ethylenediamine tetra-acetic acid solution.
  • A human HCC cell line (HA 22T/VGH) was studied for comparison.
  • RESULTS: Addition of AmB showed no influence on epirubicin cytotoxicity in two patients (one partial resistant HCC and one epirubicin-sensitive cholangiocarcinoma; 25%), augmentation of the epirubicin cytotoxicity in two patients (one total resistant HCC, partial resistant HA 22T/VGH cell line and one epirubicin-sensitive HCC; 37.5%), and decrease of epirubicin cytotoxicity in the remaining three (one partial resistant and two epirubicin-sensitive HCC; 37.5%).
  • CONCLUSIONS: Amphotericin B has a discordant influence on epirubicin cytotoxicity in primary cultured hepatic malignant cells.
  • Application of AmB in the systemic chemotherapy of primary hepatic malignancy should be limited to patients with positive AmB effect evaluated by an in vitro sensitivity test such as the present method.
  • [MeSH-major] Amphotericin B / therapeutic use. Anti-Bacterial Agents / therapeutic use. Antibiotics, Antineoplastic / adverse effects. Epirubicin / adverse effects. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Culture Techniques. Cell Proliferation / drug effects. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Drug Interactions. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509865.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


99. Kurzer E, Leveillee RJ, Bird VG: Combining hand assisted laparoscopic nephroureterectomy with cystoscopic circumferential excision of the distal ureter without primary closure of the bladder cuff--is it safe? J Urol; 2006 Jan;175(1):63-7; discussion 67-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining hand assisted laparoscopic nephroureterectomy with cystoscopic circumferential excision of the distal ureter without primary closure of the bladder cuff--is it safe?
  • PURPOSE: We have previously described our technique of combining HAL-NU using early ureteral ligation with simultaneous cystoscopic circumferential excision of the distal intramural ureter without primary closure of the bladder cuff.
  • Two patients were noted to have distant metastases to the liver, lung and bone at 1 and 3 months postoperatively, respectively.
  • One patient was found to have distant metastases to the liver and retroperitoneal lymph nodes 2 years after surgery.
  • CONCLUSIONS: HAL-NU with cystoscopic excision of the distal ureter is feasible, safe and effective for upper tract transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystoscopy. Laparoscopy / methods. Nephrectomy / methods. Ureter / surgery. Ureteral Neoplasms / surgery. Urinary Bladder / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406870.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer; 2007 Apr 1;120(7):1444-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.
  • Recently increasing reported data have suggested that only a small subset of cancer cells possess capability to initiate malignancies including leukemia and solid tumors, which was based on investigation in these cells displaying a distinct surface marker pattern within the primary cancers.
  • CD133 is a putative hematopoietic and neuronal stem-cell marker, which was also considered as a tumorigenic marker in brain and prostate cancer.
  • We hypothesized that CD133 was a marker closely correlated with tumorigenicity, since it was reported that CD133 expressed in human fetal liver and repairing liver tissues, which tightly associated with hepatocarcinogenesis.
  • Our findings showed that a small population of CD133 positive cells indeed exists in human hepatocellular carcinoma (HCC) cell lines and primary HCC tissues.
  • From SMMC-7721 cell line, CD133+ cells isolated by MACS manifested high tumorigenecity and clonogenicity as compared with CD133- HCC cells.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma, Hepatocellular / metabolism. Glycoproteins / metabolism. Liver Neoplasms / metabolism. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Liver Cirrhosis / metabolism. Male. Mice. Mice, Congenic. Mice, Inbred NOD. Mice, SCID. Middle Aged. Neoplasm Proteins / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17205516.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Peptides
  •  go-up   go-down






Advertisement